That has changed. AI is now wonderful at navigating these public datasets, and the opportunity in front of you is real. Here are the seven sources we covered, with the way I would love for you to use each one.

1. CMS Hospital Care Compare

Think of it as Yelp for hospitals. Star ratings across categories like HCAHPS, readmissions, and patient safety. Drill into the sub-scores and you can see where a hospital has room to grow, whether that is nurse communication, surgical site infections, or ED throughput. I recently pulled left-without-being-seen rates and median ED wait times for a client’s prospect list. His outreach completely transformed, and he started getting responses from people who used to ignore him.

2. Medicare Cost Reports (CMS HCRIS)

This one is my favorite. Every hospital CFO files it, and it is wonderfully detailed. Net patient revenue, payer mix, department-level costs, supply cost ratios, even transplant program detail for facilities that have one. Spend a little time inside your top accounts’ cost reports and you will walk into meetings with the kind of context that earns respect right away. Better yet, build your own metric on top of it. Revenue per operating room. Supply spend per discharge. Something that helps the CFO see her own hospital from a fresh angle.

3. Leapfrog Hospital Safety Grade

A third-party A through F grade across 28 national measures, including hospital-acquired conditions, surgical site infections, medication safety, and nursing ratios. A hospital sitting at a C wants to be a B. If your solution helps move the needle on any of those measures, this is where your opening lives. Handle it gently in the conversation and you will be welcomed as a partner.

4. IRS Form 990 (ProPublica Nonprofit Explorer)

For nonprofit hospitals, the 990 shows you top vendors, executive compensation, research spending, unrestricted net assets, and strategic priorities. I do not always pull it into the deck. I use it to walk into the room prepared, so that when a topic comes up I already know the number. Preparation builds trust faster than any case study, and your prospect will feel it.

5. CMS Open Payments

The Sunshine Act database. It shows which manufacturers are paying which physicians, and for what. Use it as intelligence, not ammunition. If a surgeon is a key opinion leader in ankle reconstruction for one vendor, that does not block you. It tells you what conversation to have and what conversation to skip. It is also a quiet way to spot joint-venture and referral opportunities in non-competing categories.

6. Annual Reports and Strategic Plans

For-profit systems publish investor decks loaded with growth strategy, service line investments, and AI initiatives. Nonprofit hospitals are required to publish strategic plans, often called community reports, every three years. These include community health needs assessments. If a hospital’s community has a high diabetic population and the plan calls for mobile outreach, you already have your opening line and a beautiful way to position yourself as a partner.

7. State Certificate of Need Filings

Thirty-five states still require hospitals to file public applications to add beds, expand facilities, or acquire major equipment. This is the rarest source on the list, and it is forward looking, so you can see what a hospital plans to do twelve to twenty-four months out. New surgical centers. Bed expansions. Hospice growth. This is opportunity you can prepare for before your competitors even know it exists.

A note before you go

The data is half the work. The other half is your thinking, and how you put unique insights together to bring real value to hospital executives. That is how you earn the meeting. Not by knowing what they already know, but by offering a point of view they have not seen before.

What I want most for you is the orchestration. Walk in with three or four specific points that connect their numbers to a fresh point of view and to your solution. Bring the rest in conversation.

If you would like help building this

If you would like to build this strategy into the way you and your team sell, this is the work I do with clients every day.

Email me at lisa@lisatmiller.com.

Or schedule a meeting with me: https://calendly.com/lisa_t_miller/30min

I would love to help you win.

Lisa

Yesterday I published a piece on how C-suite access is earned, never expected. The response was significant, and the conversations that followed, with individual sellers and with the sales leaders who run their teams, surfaced a pattern I want to address directly today.

When I describe the mechanics of Strategy One, pulling a hospital’s Medicare Cost Report, calculating a Cost-to-Charge Ratio, identifying a length-of-stay variance against the IPPS benchmark, building a one-page margin leak brief, what I hear back from sales professionals and sales leaders alike is some version of this: I am not sure my team could actually do that. We have been selling into hospitals for years, and we do not know how to read a Cost Report worksheet, or what a credible margin variance estimate looks like.

If you felt any of that reading yesterday’s piece, I want you to stay with me. The honest answer to where that feeling comes from, and what it actually means for your company and your sales success, is the entire reason I am writing this follow-up.

Most companies selling into hospitals will not earn C-suite access.

Not because their reps are not talented. Not because they are not hungry.

Because they have not built the systems, skills, and support their reps would need to do the work.

Why the gap exists

Most healthcare sales training, including the well-known and well-respected methodologies, gives a rep a framework for qualifying a deal, structuring a discovery call, mapping a buying committee, and handling objections. Those are real skills. They matter. I love the Challanger Sale. A Blue Sheet has tremendous value.

However none of those programs will teach a healthcare sales executive how to read a Medicare Cost Report. None will walk them through what a hospital CFO is actually looking at when reviewing surgical service line profitability. None will show them how the annual IPPS Final Rule reshapes the economics of the very account they are trying to sell into. None will explain why the relationship between charges and costs is the single most important number on the financial page for the executive they want to reach.

That is not a flaw in those programs. They are sales methodologies. What reps need layered on top of them is fluency in hospital finance that matters to the CFO.

Most companies do not hire for it. Most onboarding does not include it in depth and the typical rep arrives at a hospital account fluent in the language of their product and average in the language of the buyer.

That is the gap. It is structural, not personal. And it is the reason most outreach from a vendor sales team into the C-suite gets ignored.

Why the gap is good news

Here is the part I want you to hear clearly.

The gap most companies do not invest in closing is the most valuable territory in healthcare sales.

Let me show you the math the way I see it.

If a thousand reps are calling on the same large health system this quarter, roughly 950 of them are leading with their product. Maybe 40 of them are well-trained on a sales methodology and running a clean process. Maybe 5 of them have built something approaching a real financial point of view on the account. Maybe 1 has actually opened the Medicare Cost Report and triangulated the data against MedPAR and the IPPS tables before reaching out.

That one rep is the rep who gets the meeting. And behind that one rep, almost always, is a company that made a decision the other companies did not.

When the CFO’s inbox surfaces an email that references their actual DRG 470 cost variance, their actual implant Cost-to-Charge Ratio, their actual length of stay against the geometric mean, that email does not get sorted as a vendor pitch. It gets sorted as something worth a reply. In a single exchange, the rep has demonstrated what the other 999 cannot: they understood what it is like to sit in the CFO’s seat. And the company behind them has demonstrated something even rarer, which is that they decided the work was worth doing.

That is the moat. And the most important thing I can tell you about it is this: the moat is learnable, and it is buildable across a team - especially if the team is coachable.

What building the competency actually requires

It takes time. It takes intention. It takes reading source documents most reps will never open. It is a competency. It can be built deliberately, in months, by any seller willing to do the work, and by any company willing to sponsor it.

The proof that the gap is real is in the reaction it produces on the other side of the desk.

When I presented my findings to CFOs, the common response was, “I have never seen this type of analysis before.”

Sit with that sentence for a moment. CFOs of major hospitals, people who field vendor presentations every week and review board-level financial reports every month, telling me they had never seen this kind of analysis. Not because the analysis was exotic. Not because the data was proprietary. Everything I built came from publicly available sources: the Medicare Cost Report, the IPPS Final Rule, MedPAR. The data was sitting there, free, for any vendor who wanted to use it.

The reason the CFO had never seen this analysis was simpler. No vendor had ever built it for them.

That is the moment the room changes. The conversation stops being a sales call and becomes a conversation between two people looking at the same problem from two different seats. From that point forward, the vendor is no longer competing on price or product. They are competing on insight, which is a category most of their competitors are not even entering.

And what insight requires is strategic thinking grounded in deep healthcare expertise.

That is what is on the other side of this work. And that is why it is worth doing.

At the individual level

You start with the Medicare Cost Report. You pick one hospital you care about, ideally one in your active pipeline. You download their most recent HCRIS submission. You open Worksheet A and Worksheet C, Part I. You spend an evening, then another, then another, until you can explain in plain language what a Cost-to-Charge Ratio is and why it matters more than the gross charge. You learn to read Worksheet D-1 the same way.

Then you move to the IPPS Final Rule for the current fiscal year. You learn what the relative weight is for the highest-volume DRGs in your space and what the base payment rate produces for that hospital. You learn what the geometric mean length of stay looks like next to that hospital’s actual length of stay. You start to see the gaps the CFO is being asked about by the board.

Then you layer in MedPAR. You learn how to read aggregated claim-level performance by DRG, and how to compare the hospital’s actual reimbursement against what the IPPS tables predict it should be.

Then you write a one-page brief on that hospital. Just one. You do not send it yet. You write it because the act of building it is what teaches you. By the time you finish the third version, you will know more about that hospital’s financial reality than the rep who has been calling on it for two years.

That is the work. It is not glamorous. It is uncomfortable for a while, because being a beginner in financial analysis is uncomfortable for anyone. But that discomfort is the price of admission to the C-suite conversation.

What I have described is one entry point. Every company selling into hospitals can build a financial analysis that connects what they sell to what the CFO is being measured on. A capital equipment company can anchor on case-level margin. A supply chain partner can anchor on purchased services as a percentage of net patient revenue. A workforce technology vendor can anchor on labor expense per adjusted discharge. The data is sitting in public sources for any company willing to pull it.

The point is not the specific analysis. It is the discipline of building one.

At the company level

The same work, sponsored at the company level, looks very different. It is not an individual rep’s evening study. It is a structured commitment from sales leadership.

Its a strategy.

It looks like a hiring filter that asks candidates to read a sample Cost Report excerpt and discuss what they see. It looks like onboarding that includes financial fluency as a graded module, not an optional reading list. It looks like protected time on the rep’s calendar each week to build account-level briefs, with that time treated as carefully as a forecast call. It looks like internal analyst capacity, or an external partnership, that helps reps pull and validate the data without losing a day to it.

It looks like account reviews where the rep’s brief on a target hospital is critiqued by peers before it ever leaves the building. It looks like a recognition and comp system that rewards the depth of an account brief, not just the velocity of activity.

Most companies will not build this. They will say the right things in a kickoff and then default to activity metrics and pipeline coverage by the second quarter. The companies that do build it stop running the same uphill battle on every account, and the gap between their results and the rest of the market becomes the kind of margin a competitor cannot close by hiring more reps.

Why I am telling you this

I have worked across the desk from hospital CFOs for 25 years. I have served in interim leadership roles inside health systems. I have built the financial analysis that goes into board packets. The reps I have respected most over those decades, the ones who consistently won the meetings I would not have given to others, were not the ones with the polished decks or the longest case study libraries. They were the ones who could open a Cost Report and tell me something I did not already know about my own hospital. And behind almost every one of them was a company that had chosen to make that fluency a non-negotiable part of how they sold.

That is the profile. It is not common. It is not supposed to be. And that is precisely why it works.

So if you read yesterday’s article and felt the mechanics were out of reach, here is what I want to leave you with. The gap you felt is the gap. It is real. It is also the most valuable thing in healthcare sales to close. The companies that close it stop chasing access. Access starts coming to them.

If you lead a sales organization selling into hospitals and you want to build this competency across your team deliberately, on a structured path, that is the work I do with company sales organizations and with the individual sellers who want to invest in their own ceiling.

The C-suite selling discipline I described yesterday sits on top of this competency.

You can reach me at lisa@lisatmiller.com.

The companies that will not do this work are not your competition. The companies that will, are.

The good news is there are not many of them. Yet.

———

For a conversation about building C-suite financial fluency inside your sales organization, reach me directly at lisa@lisatmiller.com.

Why outreach alone will not get you in the room, and the three strategies that will.

If I had to name the single most common frustration I hear from sales leaders and individual contributors, it would be this one: I cannot get a meeting with the C-suite. I have called, I have emailed, I have followed up, and nothing is working.

I hear it every week. It comes from reps selling clinical products, capital equipment, services, software, consulting. It comes from founders trying to close enterprise health systems. It comes from seasoned account executives who have been hitting quota for years and suddenly cannot crack a specific account.

So let me put a stake in the ground, because this is the foundation of everything I teach about selling to hospitals.

Access is earned. It is never expected.

That one sentence will change the way you build your pipeline if you let it. The frustration most sellers carry is built on a quiet assumption: that outreach should be enough. That because you sent a thoughtful email, or left a polite voicemail, or made a LinkedIn connection, a meeting should follow. It will not. And it should not.

Hospital executives are not withholding meetings because they are difficult. They are withholding meetings because there are not enough hours in their day to take one that does not move their priorities forward. The CFO has a multi-billion-dollar budget, payer negotiations, capital decisions in motion, and a board to answer to. The COO is solving for throughput and labor. The CMO is balancing quality, safety, and physician relationships. None of them owe you their time. They will give it to you if, and only if, you have earned it.

So the question becomes simple, and it is the one I want you to sit with: what does value actually look like, defined from their seat, not yours?

Why “value” has quietly stopped meaning value

Most sales training in our industry teaches you to lead with the same three buckets: reduce cost, increase revenue, reduce risk. Those are true. They are also, at this point, generic.

The most common move I see reps make in the name of value is sending a case study. I love a good case study. They have their place. But pause and think about it from the executive’s side of the table.

Right now, this week, that executive’s inbox is full of case studies. Every rep is sending one. When everyone leads with the same proof point, the proof point stops working. Worse, a generic case study sent cold signals something the sender probably does not intend to communicate. It signals that the conversation is about the vendor, not the executive. It is transactional. The executive can feel it.

So if generic case studies, broad ROI claims, and templated outreach are not the path, what is?

There are 3 out of the 8 strategies I coach my clients on. Let me take them one at a time.

Strategy one: lead with a unique insight about their hospital, not your solution

This is the strategy that separates the rep who gets the meeting from the rep who keeps following up.

A unique insight is not a stat you pulled from Google or a generative AI summary of the industry. It is your own thinking, applied specifically to the hospital you are trying to reach, drawing on data and experience the executive themselves may not have stitched together.

Here is a concrete example. Say your service is operational improvement in the OR. The generic version of your pitch is, “We help hospitals improve OR throughput, and our clients have seen meaningful gains.” That gets a polite no.

Now compare that to this. You pull the executive’s Medicare Cost Report. You go into surgical line profitability by DRG. You look at DRG 470 or DRG 475, cross-reference against two other publicly available data sets, and you build a one-page executive brief that says: based on three publicly reported data points, here is what we are seeing inside your DRG 475 profile, here are the three areas with the most room to improve, and here is what that improvement is plausibly worth.

Let me show in detail what I mean:

Leveraging Medicare Cost Reports and Public Data for DRG-Level Profitability Outreach

By triangulating data from the Medicare Cost Report (HCRIS), the CMS Inpatient Prospective Payment System (IPPS) Final Rule Impact File, and the MedPAR dataset, you can construct a highly credible, data-driven narrative. This approach moves the conversation from a vendor pitch to a peer-level financial review.

The Three Pillars of Public Data

To build a compelling executive brief, you must synthesize three distinct but complementary datasets:

1. The Medicare Cost Report (HCRIS)

The Healthcare Provider Cost Reporting Information System (HCRIS) contains the annual Medicare Cost Reports submitted by all Medicare-certified hospitals. This is the foundational document for understanding a hospital’s true cost structure, beyond what they charge.

Key Worksheets for Surgical Profitability:

• Worksheet A: This worksheet maps the hospital’s trial balance expenses to specific Medicare cost centers. It shows the raw, unallocated costs for departments like the Operating Room (Line 50), Medical Supplies Charged to Patients (Line 71), and Implantable Devices Charged to Patients (Line 72).

• Worksheet C, Part I: This is arguably the most critical worksheet for profitability analysis. It calculates the Cost-to-Charge Ratio (CCR) for each ancillary department. By dividing total costs by total charges, the CCR allows you to convert a hospital’s gross charges on a patient claim into an estimated actual cost. For surgical lines, you will look specifically at the CCRs for the Operating Room and Implantable Devices.

• Worksheet D-1: This worksheet computes the inpatient operating cost. It provides the average cost per diem for routine care (e.g., Med/Surg beds, ICU). When combined with the length of stay for a specific DRG, this allows you to estimate the routine room and board costs for those patients.

2. The CMS IPPS Final Rule Impact File and Tables

Published annually, the IPPS Final Rule dictates how Medicare pays for inpatient stays. The associated data tables provide the payment parameters for every DRG.

Key Data Elements:

• Relative Weight: Each DRG is assigned a relative weight that reflects the average resources required to treat patients in that group compared to the average Medicare case. For example, DRG 470 has a specific relative weight that, when multiplied by the hospital’s base payment rate, determines the base reimbursement.

• Geometric Mean Length of Stay (GMLOS): The IPPS tables publish the national geometric mean length of stay for each DRG. This serves as a critical benchmark. If a target hospital’s average LOS for DRG 470 is 3.5 days, but the national GMLOS is 2.2 days, that variance represents a quantifiable margin leak.

3. The MedPAR Dataset

The Medicare Provider Analysis and Review (MedPAR) file contains claim-level data for all Medicare Part A inpatient discharges. While the raw file is massive, aggregated MedPAR data (often available through secondary analytics platforms or CMS public use files) provides hospital-specific performance metrics by DRG.

Key Data Elements:

• Average Total Charges by DRG: The average amount the hospital billed for DRG 470 or 475.

• Average Medicare Payment by DRG: The actual average reimbursement received.

• Average Length of Stay by DRG: The hospital’s actual average LOS for that specific procedure.

The Analytical Methodology: Connecting the Dots

To build the executive brief, you must connect the data from these three sources to estimate the hospital’s true margin on a specific DRG.

1. Determine the Revenue: Use MedPAR data to find the hospital’s average Medicare payment for DRG 470.

2. Estimate the Costs:

◦ Take the hospital’s average total charges for DRG 470 (from MedPAR).

◦ Apply the hospital’s overall or department-specific Cost-to-Charge Ratios (from HCRIS Worksheet C) to those charges to estimate the true cost of the case.

◦ Pro-Tip: For orthopedic and spinal procedures, isolate the implant charges and apply the specific CCR for “Implantable Devices Charged to Patients” (Worksheet C, Line 72). This often reveals that high implant costs are destroying the margin.

3. Calculate the Margin: Subtract the estimated true cost from the average Medicare payment.

4. Identify the Variance: Compare the hospital’s estimated cost and actual Length of Stay against the national averages (from the IPPS Final Rule tables).

The One-Page Executive Brief Template

This template is designed to be sent directly to a hospital CFO or VP of Finance. It uses their own data to highlight a specific financial vulnerability and proposes a targeted discussion.

CONFIDENTIAL EXECUTIVE BRIEFING Prepared For:

[Executive Name], [Title], [Hospital Name] Subject: Margin Variance Analysis: Surgical Service Line (MS-DRG 470 & 475) Date: [Date]

Executive Summary Based on an analysis of [Hospital Name]’s most recent Medicare Cost Report (FY [Year]) and CMS MedPAR claims data, we have identified a significant margin compression within your high-volume orthopedic and spinal surgical lines, specifically MS-DRG 470 (Major Joint Replacement) and MS-DRG 475.

While these procedures represent a critical revenue stream, your facility is currently underperforming national benchmarks in cost-to-serve and length of stay, resulting in an estimated margin leak of $[X.XX]M annually on Medicare volume alone.

Data-Driven Observations (Based on Publicly Reported Data)

1. Implant Cost Variance (HCRIS Worksheet C, Line 72) Your Cost-to-Charge Ratio (CCR) for Implantable Devices is currently [X.XX]. When applied to your average implant charges for DRG 470, your estimated implant cost per case is $[X,XXX]. This is [X]% higher than the regional average of $[X,XXX]. This suggests an immediate opportunity for vendor contract renegotiation or physician preference item (PPI) standardization.

2. Length of Stay (LOS) Drag (MedPAR vs. IPPS Final Rule) According to recent MedPAR data, your average Length of Stay for DRG 470 is [X.X] days. The CMS Geometric Mean Length of Stay (GMLOS) for this DRG is [X.X] days. This [X.X] day variance, when multiplied by your routine per diem cost of $[X,XXX] (derived from HCRIS Worksheet D-1), represents an excess cost of $[X,XXX] per discharge.

3. Operating Room Efficiency (HCRIS Worksheet A & C, Line 50) Your Operating Room cost center shows a fully allocated cost per minute that exceeds peer facilities of similar size and acuity. This indicates potential bottlenecks in OR turnover times or over-allocation of overhead, compressing the margin on fixed-reimbursement DRGs.

The Financial Impact By closing the gap to the 50th percentile benchmark in just two areas—Implant Costs and Length of Stay—[Hospital Name] could realize an estimated margin improvement of $[X,XXX] per Medicare discharge for DRG 470. Across your annual Medicare volume of [X] cases, this represents a $[X.XX]M bottom-line opportunity.

Proposed Next Steps: This analysis is based on publicly available CMS data. We have developed a proprietary methodology to help facilities like [Hospital Name] capture these specific margin opportunities without disrupting clinical workflows.

If you are open to a further discussion on our strategies, lets schedule a call to review the underlying data model and discuss how we may be able to provide our O.R. financial improvement strategies to your hospital.

That is not a pitch. That is consulting.

And it gives the executive something none of your competitors are giving them: thinking that is specific to their hospital.

I hear the objection all the time: “if I give it away, they will take the brief and ignore me.”

First, they are already ignoring you, so the downside is zero.

Second, they will not.

Their reaction is going to be the opposite. They are going to think, if this is what they put in a one-page brief I did not even ask for, what would they bring to a working conversation? What would they bring as my advisor? What would they bring if I were actually using their product or service? That is the line of thought that opens the calendar.

Strategy two: publish original content only you could have written

The second way to earn access is to be visible in the market with original thinking that no one else can replicate.

I am not talking about a fluffy blog post that any AI tool could generate in ninety seconds. I am talking about real intellectual work. A quarterly industry review on a topic you own. A point of view on a CMS policy shift, with the implications spelled out. An original research piece pulled from your customer interviews and your team’s collective field intelligence.

The test is simple. Could a generalist sit down and produce the same piece in an afternoon? If yes, you have not built a moat. The piece you want to produce is one where the answer is no. It is the piece authorities and associations start citing because it is the cleanest articulation of a problem they have all been trying to name. It is the piece an executive forwards to a colleague and says, I want us to think about this.

That kind of content earns access on autopilot, because executives reach out to the author. You become a known voice on a specific topic, and the meeting requests start coming the other direction.

Strategy three: show up differently in how you reach out

The third move is more tactical, and it amplifies the first two. Most outreach looks identical: same templated email, same LinkedIn message, same cadence. So when something different lands in the executive’s inbox, they notice.

A short asynchronous video is one way to do this. Thirty seconds, looking into the camera: I put together a one-page brief specific to your hospital and your surgical service line. I would like to send it over. Would that be useful? That is a very different ask than “do you have 15 minutes next week.” You are not asking for time. You are offering value, and asking permission to deliver it.

Another version is a no-charge executive brief delivered to the team. Thirty minutes, on a specific topic that matters to them, no pitch attached. Hospitals appreciate this when the content is genuinely useful, and it gives you a chance to meet the team in a low-pressure setting where you are the one giving, not asking.

One more variation that works well: send the executive a piece of original content you have written and ask for their feedback. Not a pitch. A genuine ask: I put this together, and I would value your perspective. Is there anything you would add, change, or push back on? Executives respect people who are willing to be edited, and it positions you as a peer, not a vendor.

In all three tactics, the through line is the same. You are not asking for access. You are demonstrating, in advance and in concrete form, the kind of value you would bring once the relationship existed.

The bigger picture

Marc Benioff has said for years that every meaningful enterprise deal Salesforce closed in its early growth years involved the CEO. Not procurement. Not the line manager. The CEO. That is not a vanity statistic. It is a discipline. Salesforce built a motion that earned that level of access on every important deal.

You can build the same motion. It does not replace what you already use. If your team runs Challenger, MEDDIC, or Miller Heiman, keep them. They are good. Layer on top of them a C-suite selling discipline that treats access as something earned through unique insight, original content, and differentiated outreach.

That is the missing layer. When my clients install it, the results are not incremental. They are material.

So the next time you feel the frustration of a quiet inbox, do not ask why they are not responding. Ask the harder question: what have I given them that would make a response inevitable?

That is where the work is. And that is where the meetings are.

———

For a conversation about building a stronger C-Suite strategy inside your company, reach me directly at lisa@lisatmiller.com

The market has quietly changed the rules

The research is no longer ambiguous. In the most recent Edelman–LinkedIn B2B Thought Leadership Impact Report, 54% of C-suite executives say they spend an hour or more every week reading thought leadership, and 75% report that a single piece of it has led them to research a product or service they were not previously considering (LinkedIn Marketing Solutions). Nine in ten say consistent, high-quality thinking makes them measurably more receptive to outreach. And 70% admit a piece of someone else’s thought leadership has, at least occasionally, made them question whether they should keep working with an existing supplier.

That is not a content marketing finding. That is a competitive intelligence finding.

At the same time, Corporate Visions’ analysis of more than 150,000 deals found that 79% of buyers say sellers look the same — and that a seller’s ability to differentiate is one of the strongest predictors of winning the deal. In high-stakes purchases, the buying experience and the framing of the problem now explain 59% of the decision, while the offering itself explains only 41%.

Translation for anyone selling into the C-suite: the asset that frames the problem wins more often than the product that solves it. Executives are not short on vendors. They are short on language for what is actually broken on their P&L.

That is the gap a Core Authority Asset is built to close.

Thought leadership versus a Core Authority Asset

Most “thought leadership” today is a stream — posts, newsletters, podcasts, decks, lead magnets, and one-off articles, each restarting the conversation from zero. It produces awareness. It rarely produces authority. And it almost never survives the journey from a champion’s inbox to an executive committee.

A Core Authority Asset is different in kind, not degree.

It is the single, deliberate, market-facing artifact upon which your entire commercial strategy is allowed to depend. It is a concentrated, high-signal expression of your hard-won point of view — architected with executive-grade positioning, original frameworks, a narrative arc, proof points, and crystal-clear takeaways — so that a C-suite executive can read it in one sitting, instantly recognize their own strategic reality in it, and confidently champion it (or forward it to their board, peers, and other key stakeholders) with their own reputation attached.

It is not a brochure. Not a deck. Not a lead magnet. Not a one-off article.

It stops being “content” the moment it becomes the reason deals move forward when you are not in the room.

Why a unique point of view is now the differentiator

The Edelman–LinkedIn data is blunt about what earns executive attention: thought leadership that references strong research and data, that helps buyers understand their challenges and opportunities in a new way, and that offers concrete guidance — not recycled advice (LinkedIn). The C-suite, in other words, is allergic to anything that sounds like everyone else.

Corporate Visions calls this the Value Wedge — the intersection of what is unique to you, important to the buyer right now, and defensible with evidence. Without it, conversations collapse into parity, and the buyer either picks the incumbent or picks on price.

A Core Authority Asset is your Value Wedge made portable. It is the place where your point of view stops living in your head and starts living in executive inboxes, board pre-reads, and Monday morning exec syncs. It is the document a COO underlines on a Saturday and brings into a leadership meeting on Tuesday — because something on the P&L is not moving and your framing names it more precisely than anyone else’s.

What a Core Authority Asset actually does

When it is built correctly, a Core Authority Asset performs four jobs at once — jobs that scattered content cannot.

1. It translates expertise into the language of the executive committee. Champions trust you. Executives need a frame. A Core Authority Asset gives the champion something forwardable that survives the journey upward without you in the room.

2. It converts attention into a decision-room conversation. Edelman’s research shows that hidden buyers — the unseen influencers who stall or accelerate 40% of B2B deals — actively seek out perspective-shifting content and will advocate for less familiar vendors when the thinking is strong enough (Edelman). A Core Authority Asset is built to be the artifact those hidden buyers reach for.

3. It compounds authority instead of resetting it. Every talk, post, proposal, podcast, and sales conversation now points back to the same defensible asset. Visibility stops being a treadmill and starts being a flywheel.

4. It justifies premium pricing. Edelman finds that effective thought leadership makes buyers “willing to seek you out — and even pay extra for your expertise” (Edelman 2024 Report). Authority, once recognized, is the most defensible margin in B2B.

The strategic test

If you want to know whether you have a Core Authority Asset or merely a portfolio of content, ask three questions.

· Could a prospect’s COO read it on a Saturday and bring it into Monday’s executive sync — with their own reputation attached?

· Does every talk, post, proposal, and podcast you produce point back to the same defensible argument, or does each one start the conversation over?

· Is there a single piece of intellectual capital in your business that makes the case for you in your absence — inside rooms your calendar will never reach?

If the answer to any of these is no, you do not have an authority problem. You have an asset problem.

The bottom line

The market is paying a premium right now for one thing in particular: a clear, original, evidence-backed point of view delivered in a form executives actually consume. Sellers who look the same lose. Sellers who frame the problem better than the incumbent — in a single, forwardable artifact — win the deal, the price, and the next one after it.

A Core Authority Asset is not more content. It is the one piece of intellectual capital that turns your expertise into the kind of recognized authority that executives act on, champion, and pay for — without you having to sell one conversation at a time.

It is the asset your commercial strategy is finally allowed to depend on.

The Strategic Influence™Workshop

I wrote The Executive Yes Book and developed The SEAD System because I’ve lived the exact challenge you’re facing, which is doing exceptional work that should open C-suite doors… yet still watching high-value deals stall because your expertise hasn’t been translated into the kind of commercial authority executives can immediately act on and forward upward.

That’s exactly what Chapter 2 in The Executive Yes book is about.

I’m opening the founding cohort of the Strategic Influence™Workshop exclusively to my community. You can learn more about the live two-day workshop here.

What it is:

A live, two-afternoon intensive (90 minutes each) built 100% around Chapter 2. In just two sessions you will walk away with your Core Authority Piece — the single market-facing asset that turns your expertise into authority executives recognize, trust, and forward with their own reputation attached.

What you’ll leave with:

A finished architecture for your Core Authority Piece (positioning, POV, section-by-section outline, frameworks, narrative arc, and proof points)

Your sharp one-sentence C-suite positioning

A complete 12-month thought-leadership and distribution strategy (pre-call sequence, mid-deal references, partner/content plan, launch plan, and first decisive action already on your calendar)

The exact way to stop selling one conversation at a time and start letting the asset do the heavy lifting

Dates & Times (both sessions are live with me):

• Day One – Wednesday, June 10 · 2:00 – 3:30 PM ET

• Day Two – Thursday, June 11 · 2:00 – 3:30 PM ET

Everything is recorded and you’ll have 12-month access to the full library.

Founding-Cohort Extras (only for this first group):

Chapter 2 Strategic Influence™ workbook (diagnostic + templates)

Private founding-cohort community (get real-time feedback)

Live group office hours with me 30 days after Day Two

Regular price after the founding cohort will be $1,000. As a verified book owner, your founding-cohort price is just $600 (or two payments of $350).

→ Reserve Your Founding Seat Here:

Spots are deliberately limited so I can work directly with every participant. Once the founding cohort closes, this exact live format and pricing will not be repeated.

This intensive is where Chapter 2 becomes the asset that starts moving your biggest deals forward.

I’d love to see you there.

-Lisa

PS - A Core Authority Asset is the single, deliberate, market-facing artifact upon which your entire commercial strategy is allowed to depend. It is a concentrated, high-signal expression of your hard-won point of view — architected with executive-grade positioning, original frameworks, narrative arc, proof points, and crystal-clear takeaways.

In short: it is the one piece of intellectual capital that turns your expertise into the kind of recognized authority that executives act on, champion, and pay for — without you having to sell one conversation at a time.

PPS - You will leave the two day workshop with your own Core Authority Asset that opens doors to the Executive Suite.

https://strategic-authority-lab.lovable.app

In episode sixteen of “Selling to Healthcare,” Lisa T. Miller takes on one of the most persistent myths in modern B2B sales — the idea that executives can no longer make meaningful buying decisions without full committee consensus. Drawing on behavioral economics, neuroscience, and real-world case studies, Lisa explains what actually drives the final yes and why the brands that win in healthcare aren’t the loudest or the most feature-rich, but the most trusted.

She unpacks the psychology behind executive decisions — from the powerful role of emotion and personal value, to Kahneman’s Prospect Theory and the risk-aversion that quietly shapes every C-Suite choice. Lisa makes the case that B2B buying is far more emotional than B2C, and that fear of professional risk is often a stronger motivator than the promise of a better outcome.

Lisa then walks through the five-stage architecture of the modern executive buying journey, sharing the data sellers need to understand: most purchase requirements are defined before vendors are ever contacted, peer networks dominate shortlist creation, buying committees have ballooned to 10+ people, and 86% of B2B purchases stall somewhere along the way. She illustrates how the committee builds awareness while the executive still decides — using the Merck/IBM story, where a single CEO-to-CEO conversation overturned a fully-aligned committee recommendation.

This episode offers healthcare sales professionals a clear-eyed playbook for selling to deciders, not just committees — by winning the emotional argument first, reframing the cost of inaction, investing in thought leadership long before the formal evaluation begins, and giving executives the clarity, evidence, and strategic insight to use their authority well.

Highlights of this Episode Include:

• The Myth of the Rational Executive: B2B brands drive stronger emotional connections than B2C brands — because the professional stakes of a bad business purchase are enormous, executives won’t commit without trust and emotional buy-in.

• Personal Value Beats Business Value: Buyers who see personal value are 71% more likely to buy and 8x more likely to pay a premium — only 14% will pay a premium for business value alone.

• The Kahneman Effect: Executives are more motivated to avoid loss than to acquire gain — the most effective sales narratives lead with the cost of inaction, not the benefits of action.

• The Invisible Buying Journey: 83% of buyers have mostly or fully defined their purchase requirements before they ever speak with sales — by the time you’re invited in, the shortlist is often already formed.

• Peer Networks Build the Shortlist: 73% of B2B executives rank word-of-mouth and peer recommendations as the most influential factor in deciding which vendors to consider — social proof outperforms any vendor demo.

• The Committee Informs, the Executive Decides: The Merck/IBM story shows how a unanimous committee recommendation was overturned by a single CEO-to-CEO conversation — authority still exists, it’s just less visible.

• Consensus Often Masks Risk-Aversion: Buying committees that have grown to 11, 12, or 15 people aren’t larger because decisions got more complex — they’re larger because willingness to own the tradeoff got smaller.

• The Two-Stage Brain: Decisions are made emotionally in the amygdala and justified rationally in the prefrontal cortex — if you haven’t won the emotional argument, no amount of ROI data will close the deal.

• Thought Leadership Shapes Decisions Months in Advance: Effective thought leadership engages the 95% of buyers who aren’t actively in-market, reframing assumptions and shaping decisions long before the formal evaluation begins.

• Sell to Deciders, Not Just Committees: The work isn’t to assemble a coalition large enough to remove all friction — it’s to give the executive who already has authority the clarity and strategic insight to use it well.

Read on X:

Learn about Lisa’s Services & Workshops:

• https://www.lisatmiller.com/lisa-t-miller-services

• https://www.lisatmiller.com/value-selling-training

• https://www.lisatmiller.com/value-selling

Learn more about Lisa at https://lisatmiller.com/about

Book an appointment - https://calendly.com/lisa_t_miller/30min

LinkedIn - https://www.linkedin.com/in/lisamiller/

Today I am writing about a topic that I have spent a lot of time thinking about - it’s consensus buying and consensus decision making.

While I agree that committees and alignment are important, I do not believe they are solely responsible for making decisions. In fact, in my experience, leaders are still the ones making the final call.

The traditional view of the C-suite executive as a purely rational, data-driven decision-maker—often characterized as a “Tin Man” devoid of emotion—is fundamentally flawed. Extensive research across behavioral economics, psychology, and B2B sales data reveals that executive buying decisions are deeply emotional, heavily influenced by risk aversion, and increasingly reliant on peer networks and thought leadership.

While B2B purchases are often justified with logic, return on investment (ROI) calculations, and total cost of ownership (TCO) models, the actual decision to buy is driven by personal value, trust, and the desire to mitigate professional risk. Furthermore, the modern B2B buying journey has evolved into a complex, non-linear process involving large buying committees, extensive self-directed research, and the growing influence of AI and digital communities.

This report synthesizes real-world stories, case studies, and industry research to provide a comprehensive understanding of how executives truly make buying decisions.

Part I: The Myth of the Rational Executive

For decades, B2B sales and marketing strategies have been built on the assumption that business purchases are entirely rational. The executive, it was assumed, evaluates features, compares prices, calculates ROI, and selects the objectively best option. Research consistently and emphatically proves otherwise.

Emotion Drives B2B Decisions More Than B2C

A landmark study conducted by Google and CEB’s Marketing Leadership Council (now part of Gartner) surveyed 3,000 purchasers of 36 B2B brands across multiple industries. The findings were striking: B2B brands drive more emotional connections than B2C brands, not fewer. While most B2C brands had emotional connections with 10% to 40% of consumers, seven out of the nine B2B brands studied surpassed the 50% mark .

The reason for this counterintuitive finding lies in the inherent risk of B2B purchases. When a consumer makes a poor purchase, the stakes are relatively low. However, when an executive makes a poor business purchase—particularly a large-scale technology or services acquisition—the stakes are enormous. Responsibility for a multi-million dollar software acquisition that fails can lead to poor business performance, damaged reputation, and even the loss of a job . The business customer will not commit unless there is a substantial emotional connection and a deep sense of trust to help overcome this professional risk.

The Power of Personal Value

The same Google/CEB study revealed that B2B purchasers are almost 50% more likely to buy a product or service when they see personal value in it—such as an opportunity for career advancement, or pride and confidence in their choices . Buyers who perceive high personal value are 71% more likely to buy, and they are eight times more likely to pay a premium for the solution .

In contrast, only 14% of business decision-makers are willing to pay a premium for business value alone—that is, for unique product features or differentiation . Business value is considered table stakes; personal value is the true differentiator. This means that executives are not just asking, “What does this do for my company?” They are simultaneously, and often unconsciously, asking, “What does this do for me?”

Risk Aversion and Loss Avoidance: The Kahneman Effect

Nobel Prize-winning psychologist Daniel Kahneman’s research on behavioral economics, particularly Prospect Theory, is essential to understanding executive decisions. Kahneman demonstrated that human beings are fundamentally risk-averse and will seek risk more often to mitigate a loss than to acquire a gain .

In a B2B context, choosing a new vendor or implementing a new solution is inherently risky. Executives are often hesitant to change the status quo for a potential gain. However, if their current situation is framed as a loss to be avoided—a competitive threat, a growing inefficiency, a regulatory risk—they become far more willing to take the “risky bet” of a new solution . This is why the most effective sales narratives do not lead with features and benefits; they lead with a vivid picture of the cost of inaction.

This dynamic also explains the enduring truth behind the old adage, “Nobody ever got fired for buying IBM.” Executives often default to established, safe brands not because they offer the best features, but because they offer the lowest perceived professional risk . The fear of career damage is a more powerful motivator than the promise of a better outcome.

Part II: The Architecture of the Modern Executive Buying Journey

The way executives and their organizations evaluate and purchase solutions has changed dramatically, driven by digital transformation, economic pressures, and the proliferation of information channels.

Stage 1 — Triggering the Need

Buying journeys rarely begin with a vendor’s outreach. They begin with a problem, a strategic shift, or an external trigger. Research from 6Sense shows that nearly half of buyers (49%) say economic conditions shortened their buying cycles, and 62% say those pressures pushed them to engage sellers earlier . Common triggers include:

• A competitive threat that reveals a capability gap

• A regulatory or compliance change that forces technology upgrades

• A leadership change (new CEO, CFO, or CIO) who brings a new strategic agenda

• A failed internal initiative that creates urgency for an external solution

The executive’s recognition of a problem is the true beginning of the buying journey, and it happens long before any vendor is contacted.

Stage 2 — Self-Directed Research and the Invisible Journey

Once a need is recognized, executives and their teams conduct extensive independent research—often without the knowledge of any vendor. The data on this phase is striking.

The practical implication is profound: by the time an executive engages with a vendor, the shortlist is often already formed. Winning the deal frequently depends on being present and credible during the research phase, not just during the sales process.

Stage 3 — Building the Shortlist Through Peer Networks

Executives do not build their vendor shortlists in isolation. They rely heavily on trusted peer networks, industry communities, and external advisors.

“73% of B2B marketing executives rank word-of-mouth and peer recommendations as the most influential factor in deciding which vendors to consider.” — Wynter Research (2024) [4]

This peer-driven dynamic is reinforced by the fact that 56% of buyers consult with existing product users before purchasing, a figure that rises to 71% for enterprise-level purchases . For executives, the question is not just “Does this product work?” but “Do people I respect and trust use this product?” The social proof of a respected peer’s endorsement can be more persuasive than any analyst report or vendor demonstration.

Stage 4 — The Buying Committee and the Politics of Consensus

Even when an executive has a strong personal preference, the final decision is rarely theirs alone. The modern B2B purchase involves a large, cross-functional buying group.

These large, diverse groups often have conflicting priorities and success metrics. The IT team cares about integration and security; the finance team cares about cost and ROI; the end-users care about usability. Navigating these competing interests is one of the primary reasons 86% of B2B purchases stall during the buying process .

Stage 5 — The Final Decision and the Override

The final decision is the most revealing moment in any buying journey. It is where the consensus myth most reliably collapses.

Consider the Merck and IBM story, documented by Noel Capon and Christoph Senn in Harvard Business Review. “At about the same time, the pharmaceutical giant Merck decided to outsource its data-processing system. After evaluating proposals from several potential suppliers, the managers tasked with making the selection were in agreement: The contract should go to Accenture. But shortly before it was to be signed, Merck’s CEO received a visit from Sam Palmisano, the CEO of IBM. Palmisano had risen through the ranks of IBM’s sales force and had implemented the firm’s Integrated Accounts Program, which focused on core strategic customers. He fully understood the benefits of nurturing and leveraging executive-level relationships. Merck awarded IBM the contract” (HBR, March–April 2021).

Read that carefully. The evaluation team was in agreement. The contract was about to be signed. Then a different conversation happened, at a different level, and the decision changed.

This is not an anomaly, and it is not a rogue CEO ignoring his organization. It is a CEO using new strategic information, brought to him by a peer, to reach a different conclusion than the group. The committee did real work. The committee did not make the final call. Merck’s CEO did, because with executive-level input and a clearer line of sight to the strategic stakes, he made the buying decision he believed was right for Merck.

The committee built awareness.

The CEO decided.

Part III: The Role of Thought Leadership in Shaping Executive Decisions

Because executives are conducting the majority of their research independently and before engaging vendors, the ability to influence their thinking during the research phase is critical. This is where thought leadership plays an outsized role.

The 2024 Edelman-LinkedIn B2B Thought Leadership Impact Report, based on a survey of nearly 3,500 management-level professionals across seven countries, found that thought leadership is a powerful driver of revenue—not merely brand awareness . The report’s key findings include:

• Effective thought leadership makes buyers reexamine their assumptions about their own challenges, creating demand where none previously existed.

• It can “inoculate” companies against competitors trying to poach their customers by reinforcing the customer’s confidence in their existing vendor’s strategic vision.

• It is particularly effective at engaging the 95% of business clients who are not actively seeking goods or services at any given moment—the “out-of-market” majority

The implication is that the executive buying decision is often shaped months or years before the formal evaluation process begins, through the steady accumulation of credibility and insight delivered via thought leadership content.

Part IV: The Neuroscience of the Executive Decision

Understanding how executive brains process buying decisions provides a deeper layer of insight. The decision-making process is not a single event but a two-stage process:

Stage 1 — The Emotional Decision (Amygdala): The part of the brain responsible for the actual decision is the amygdala, which is emotional and intuitive. This is where the gut feeling, the sense of trust or distrust, and the emotional response to a vendor’s narrative originate. The decision to change—to take the risk of a new vendor—is made here .

Stage 2 — The Rational Justification (Prefrontal Cortex): The rational, logical part of the brain—where language and analysis reside—is used primarily to explain and justify the decision that has already been made emotionally . This is why executives ask for ROI calculations, TCO models, and reference checks. They are not using these tools to make the decision; they are using them to validate a decision they have already made, and to provide cover if the decision is later questioned.

This two-stage model has a critical practical implication: if you have not won the emotional argument, no amount of ROI data will close the deal. Conversely, if you have won the emotional argument, the ROI data simply needs to be “good enough” to provide justification.

Key Takeaways

The following table summarizes the core principles of executive buying behavior and their practical implications.

Executive buying decisions are a complex interplay of logic and emotion, individual psychology and organizational politics, self-directed research and peer influence. The executive who asks for an ROI model is not primarily a rational calculator; they are a risk-averse professional seeking emotional confidence, personal validation, and the assurance that their decision will be respected and defensible.

The organizations that consistently win executive buyers are those that understand this duality. They build emotional connections through thought leadership and authentic relationships. They reframe the cost of inaction rather than simply promoting the benefits of action. They invest in peer networks and customer communities that provide social proof at scale. And they ensure that their own executives engage with buyers not as loose cannons or social visitors, but as genuine growth champions who bring strategic insight and a long-term perspective to every interaction.

In the modern B2B landscape, the brands that win are not the loudest or the most feature-rich. They are the most trusted.

How I can support you executive selling strategies

If your sales team is still trying to win deals by building the biggest possible coalition, you are leaving the most important conversation off the table. I work with revenue leaders to redesign their executive engagement strategy so the right C-suite relationships get built early, the right insights land at the right moment, and the final decision tilts your way. Reach out if you want your team selling to deciders, not just committees.

-Lisa

Drawing on years of working directly with hospital leadership teams — from the early CJR model and bundled payments through BPCI and into today’s conversations about TEAM, ACCESS, and rural health — Lisa explains why the real gap in healthcare sales isn’t effort or intelligence, but depth of understanding. The fluent seller reads CMS updates the way a financial analyst reads an earnings release: not for compliance, but to identify where pressure is building, which organizations are most exposed, and what the commercial opportunity looks like before the rest of the market figures it out.

Lisa walks through six CMS programs every healthcare seller needs to understand — HRRP, VBP, TEAM, ACCESS, Rural Health Transformation, and IOTA — breaking down the mechanics, the financial stakes, and the specific commercial openings each one creates. She also reframes a critical mindset shift: CMS isn’t just handing down rules. They’re identifying systemic problems in healthcare delivery and providing funded, structured solutions. The hospitals that recognize this stop treating mandates as compliance exercises and start treating them as funded pathways to performance.

This episode is a practical map for sellers who want to stop showing up with generic value-based care pitch decks and start walking into executive conversations with the specific regulatory fluency that turns the Federal Register into a prospecting calendar.

Highlights of this Episode Include:

• The Document Most Sales Teams Never Read: The annual CMS rulemaking cycle is free, public, and contains more actionable account intelligence than any paid market research report — yet most reps ignore it.

• HRRP Is Your Easiest Opening: CMS publishes each hospital’s readmission rates and penalty status every year, so you can identify exactly which target accounts are in the penalty tier and which conditions are driving their exposure before you ever make a call.

• VBP Speaks the CFO’s Language: The 2% Medicare withhold-and-redistribute model means every executive owns a piece of the score — and sellers who speak in the specific language of the four domains land a categorically different pitch.

• TEAM Is Reshaping Surgical Sales Right Now: Mandatory bundled payments make hospitals financially accountable for the full 90-day post-discharge picture, and most competitors aren’t yet speaking the language of episode cost variance, gainsharing, or beneficiary incentives.

• ACCESS Is a Board-Level Conversation: A 10-year chronic care model covering two-thirds of the Medicare population isn’t a single sales conversation — it’s a market-shaping event for care management, analytics, and patient engagement companies.

• Rural Health Is a $50 Billion Underbuilt Market: Federal investment is reshaping what rural hospitals can afford, and the competitive landscape is far less crowded than urban markets for sellers who actually speak critical access and Rural Emergency Hospital language.

• IOTA Turns Transplant Conversations Into Revenue Conversations: Up to $15,000 per case in upside payments means every transplant program leader is paying attention — if you can connect your solution to the specific performance metrics.

• Five Questions That Turn CMS Updates Into a Prospecting Calendar: Which hospitals are affected, what’s the exposure, which executive owns it, what does it require them to do differently, and what’s the timeline.

• Programs Compound — and So Does Fluency: Improving readmissions lifts VBP, TEAM, and Star Ratings simultaneously. The gap between hospitals avoiding penalties and those building real strategy has never been wider, and neither has the opportunity.

• This Week’s Fluency Move: Pull the most recent HRRP penalty data, identify the three accounts in the highest tier, and write one sentence that connects your solution to a specific driving condition in the language of the program. If you can’t write it cleanly, you’ve found the next gap to close.

To learn more about Lisa’s work visit –

Lisa’s website

Healthcare Sales Masterclass Training

Fluent In Healthcare Training

About Lisa T. Miller, MHA

Lisa T. Miller is a healthcare strategist, commercialization advisor, and former CEO of VIE Healthcare Consulting, a firm she founded in 1999 and grew into one of the Top 10 healthcare consulting firms in the United States. In 2022, VIE was acquired by Morgan Stanley Capital Partners.

Over a 30+ year career, Lisa has built a reputation for closing complex, high-value deals with hospital executives and helping organizations improve financial performance, operational efficiency, and patient outcomes. She developed a proven C-Suite selling framework that combines deep industry knowledge, education-based selling, and precise value articulation—enabling companies to access senior decision makers and secure multi-million-dollar engagements.

Lisa’s work is grounded in a rare dual perspective. She has spent decades inside hospitals advising CEOs, CFOs, COOs, and service line leaders on critical operational and financial decisions, while also building and scaling a national consulting firm that competed successfully against much larger organizations. This gives her a clear understanding of how healthcare organizations function—how decisions are made, where initiatives stall, and what drives action at the executive level.

Today, Lisa advises healthcare organizations and companies that sell into healthcare on strategy, growth, and commercialization. Her focus is on helping leaders translate complexity into clear decisions, align solutions with what health systems value, and pursue opportunities that drive measurable impact.

Dreamdata reran their B2B buyer journey research this year and quietly reset every benchmark commercial teams have been working against. Eighty-one percent of the buying cycle now happens before a buyer ever talks to a salesperson, up from seventy percent last year. The complexity inside that pre-sale window is accelerating just as fast.

The new numbers:

• 88 touchpoints in the average buying cycle, up from 76

• 4 channels involved, up from 3.7

• 10 stakeholders shaping the decision, up from 6.8

• 272 days from first impression to closed deal — nine months of you not being in the room (The Wise Marketer)

For anyone selling into hospitals, those figures should change how you think about pipeline. The hospital decision cycle was already the most layered environment in B2B. It has now gotten denser, longer, and almost entirely self-directed in the early phases.

By the time your CFO or VP of Supply Chain takes the call, the decision is largely formed. They have read your competitor’s case studies, asked a peer in their CHIME or HFMA network, watched a webinar from someone in your category, scrolled through your LinkedIn posts, and almost certainly run a few prompts through ChatGPT or Claude to stress test their thinking.

The conversation you thought was the start of the deal is closer to the middle. Often the end.

What 88 Touchpoints Actually Look Like Inside a Hospital

The Dreamdata benchmark is conservative for healthcare. A typical health system evaluation now moves through a clinical champion, an executive sponsor, supply chain, finance, IT, compliance, legal, a value analysis committee, an infection prevention review for anything touching the patient, and increasingly a chief AI or transformation officer. Ten stakeholders barely covers it for any meaningful capital purchase or service line decision.

Those stakeholders are not coordinating. They are gathering information independently, mostly through content, and arriving at the table with their own conclusions already formed. Your job between the first signal of interest and the first call is to make sure the version of you that lives in their heads is the version you would actually want representing the deal.

Most sellers have no idea what that version looks like, because they have never audited it.

What Hospital Leaders Are Carrying Right Now

Every C-suite conversation I have had this year keeps returning to the same set of pressures, and they are all converging at once.

Margins. New CMS Regulations. Workforce.

Seventy-two percent of hospital CFOs report operating margins of two percent or less, and Kaufman Hall’s January data shows the new year began with depressed margins, lower volumes, higher labor spend, and rising bad debt.

The CMS TEAM model went live January 1, 2026 — five years, mandatory, bundled payments across five surgical episodes for selected hospitals — and most participants are not operationally ready.

The HCAHPS overhaul is reshaping how patient experience translates into reimbursement under VBP. Workforce shortages persist that no signing bonus is solving. Cybersecurity exposure that the Change Healthcare attack made impossible to ignore. AI adoption pressure with no clear ROI playbook. Site of service economics moving volume out of inpatient and into ambulatory.

Each one of those is a board-level conversation. Most CFOs and COOs are juggling all seven at the same time while running the day-to-day. They have less time to take vendor calls than they did three years ago, and far more sources of information competing for the time they do have.

This is the environment in which “build a content engine” became the dominant marketing prescription across healthcare technology, devices, and services. It is also the environment in which most of those engines are quietly failing.

Why the Content Engine Model Keeps Failing

The current thinking is - buyers self-educate, so produce more for them to consume. Add posts. Add webinars. Add white papers. Add podcasts. Hire an agency. Spin up a content factory.

The factory optimizes for output, not impact. Cadence, quantity, pieces shipped per quarter, touches per account. All of it gets reported on dashboards. None of it consistently shows up in pipeline.

What hospital buyers want is the opposite of volume. They want deep nusanced insights - new innovative ways to help solve their challenges. They want a vendor who understands bundled payment structure better than their internal finance team does. They want frameworks they can take into their next executive meeting. They want a peer-level take on what hospitals three states over are doing about workforce, HCAHPS, or surgical bundles.

The most expensive content mistake healthcare commercial teams are making right now is producing more material that no hospital leader actually needs.

What High-Value Content Looks Like to a Hospital Buyer

Think about content the way a product team thinks about a software release.

Every feature is built for user impact. Every release teaches the team something that gets folded back into the next one. The product gets smarter over time.

Content for hospital buyers should work the same way. Each piece should earn its place in a CFO’s week. It should tell them something they did not already know, give them a structure they can use, or sharpen them for their next executive conversation.

Three qualities separate content that compounds from content that disappears.

It speaks at peer level. Hospital C-suites do not need vendors explaining HRRP or VBP to them. They need vendors who can engage with the second and third-order implications of policy changes most analysts have not yet surfaced. If your content could have been written by a marketing intern with a search engine, it will be read like one.

It carries a point of view. The most shared content among hospital leaders right now is sharp, opinionated work from people willing to take positions on TEAM readiness, HCAHPS strategy, and where capital should and should not be deployed. Generic best-practice content disappears the moment it lands.

It builds infrastructure rather than calendar fill. Each piece should leave something structural behind that makes the next conversation easier. A framework someone references in a board meeting. A model that gets forwarded internally. A point of view that travels through the CHIME, HFMA, ACHE, and AONL networks where your buyers actually live.

The Question No One Is Auditing: What Are Your Buyers Asking AI About You?

There is a layer of the eighty-one percent that almost no commercial team is measuring, and it is the layer where the most consequential conversations are now happening. Your buyers are not just reading content. They are asking ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews to do the work for them.

The data on this is no longer speculative. Thirty-two percent of B2B buyers now use generative AI tools as much as traditional search when researching vendors.

Forty-seven percent are using AI for market research and discovery, thirty-eight percent for shortlisting vendors, and thirty-three percent to engage with them directly.

Forty-five percent of B2B buyers said they used AI during a recent purchase, and sixty-seven percent now prefer a rep-free buying experience.

Gartner is projecting that by 2028, ninety percent of B2B buying tasks will be AI-handled — not AI-assisted, AI-handled.

The behavioral shift underneath those numbers is even more striking. The average Google user runs about four searches a day. The average AI user submits in the neighborhood of thirty-four prompts a day. Your buyers are not asking the AI one question about your category. They are asking it twenty, in conversation, with follow-ups, refinements, and cross-checks. By the time they finish a session, they have something close to a private analyst report. Your name is either in it or it is not.

In healthcare, the prompts have already evolved past “best vendors for X.” Hospital CFOs, supply chain leaders, value analysis chairs, and chief AI officers are asking questions that tie directly to the regulatory and financial pressures they are actually managing:

· Which medical device companies help hospitals reduce costs under TEAM bundled payments?

· What vendors have a defensible ROI story for the LEJR episode under TEAM?

· Who actually understands the HCAHPS digital transition and can help us protect VBP revenue?

· Which RPM platforms are being used by TEAM-mandated hospitals for the thirty-day post-discharge window?

· What companies should a system CFO talk to about workforce technology that does not require a five-year payback?

· Which AI vendors do health systems regret buying, and why?

If you do not know whether your name comes up in those answers, you do not know what is happening in the most important sixty seconds of your buying cycle. And almost no one in healthcare commercial is auditing this yet.

Why This Is Structurally Different From SEO

The instinct most marketing teams have is to treat AI search like another SEO channel. It is not. The mechanics are different in ways that change the playbook.

The answer is the result. In Google, you compete for clicks against ten blue links. In ChatGPT, there are no ten blue links. There is one synthesized answer with a small handful of cited sources. Perplexity averages 7.5 cited domains per answer; ChatGPT averages 4.1. If you are not in those four to seven slots, you are not in the consideration set. There is no page two.

Citations behave differently across engines. Perplexity shows numbered, ranked sources inline on every answer. ChatGPT cites sparingly and sometimes not at all. Claude hedges its recommendations and names brands more cautiously. Google AI Overviews collapse their citations behind a link count. Each engine selects sources from a different mix of signals, which means a brand can be visible in one and invisible in another. Cross-engine averages hide what is actually happening.

Recognition and source authority are two different battles. A buyer can hear your name mentioned in a ChatGPT answer without your domain being cited as the source. The reverse is also true. Winning one does not solve the other. Most teams are not even tracking the difference.

The signals that drive citations are not the signals that drive Google rankings. AI engines reward content that is structurally chunkable, FAQ-shaped, comparison-shaped, schema-marked, and that lives on domains the model already trusts as authoritative in your category. A blog post designed to rank for a keyword is often the wrong shape to be cited in an answer.

Personalization quietly distorts what teams see. When a marketing team prompts ChatGPT from their work account to check whether their brand shows up, they are seeing a personalized answer shaped by their own search history. The buyer asking the same question from a hospital network is seeing something else entirely. If you are auditing without a clean room, you are auditing a flattering mirror.

How to Actually Figure Out What Your Buyers Are Asking

This is the part most teams skip. They jump to optimization before they have done the diagnostic work. The right sequence is reverse first, then audit, then build.

Reverse-engineer the prompt set. Sit down with your sales leaders, your sharpest reps, and one or two friendly customers if you have them. Build a list of fifty to one hundred prompts a real hospital buyer would actually type — not the prompts your marketing team wishes they would type. Group them by buyer role (CFO, COO, VP Supply Chain, value analysis chair, chief AI officer, clinical champion), by buying stage (problem-aware, solution-aware, vendor-aware, decision-stage), and by the pressure that triggered the search (TEAM readiness, HCAHPS exposure, workforce, cybersecurity, capital allocation). The prompt set is the audit instrument. Get this right and everything else follows.

Run those prompts across all four engines in clean conditions. ChatGPT in a temporary chat with memory off. Perplexity in a private window. Claude in a fresh conversation. Gemini and Google AI Overviews from a logged-out browser. Run each prompt the same way every time, log the answer, log the sources cited, log whether your brand was named, log which competitors were named, log which categories of source the engine pulled from. This is tedious and it is also the highest-leverage research a healthcare commercial team can do this year.

Score every answer on three layers. First, brand recognition — were you named at all? Second, source authority — was your domain cited as the source the answer leaned on? Third, narrative accuracy — when you were named, was the thing it said about you the thing you actually want hospital buyers to believe? A surprising amount of the time, the AI is naming brands but mischaracterizing them. That is a fixable problem only if you know it is happening.

Map competitive citations. The domains that show up next to yours, and the domains that show up instead of yours, are telling you what the model treats as authoritative in your category. Almost always it is a mix you would not have predicted — a regulatory primary source, an analyst piece you forgot existed, a peer-reviewed study, one specific competitor’s resource page, occasionally a Reddit thread or a niche newsletter. That mix is the actual editorial board for your category right now. Your job is to be on it.

Look at the gaps as a content strategy, not a vanity metric. The most useful output of this audit is not a score. It is a list of prompts where you are invisible, prompts where you are mentioned but mis-described, and prompts where a competitor owns the answer cleanly. Each of those is a content brief. A real one. With a defined buyer, a defined intent, and a measurable target.

Re-run the audit on a cycle. AI engines update their indexes constantly. Citation positions move. Competitors publish. Models change behavior. A one-time audit is a snapshot of a moving target. The teams that win this are running a quarterly cycle at minimum, and the most aggressive ones are running monthly.

What This Means for Healthcare Commercial Teams Right Now

The hospital buyer asking ChatGPT which RPM platforms are TEAM-ready in May 2026 is making a decision that will be largely formed before any vendor knows the question was asked. That is the new front of the buying cycle. It is also where the biggest gap currently exists between the teams who are paying attention and the teams who are not.

Most healthcare commercial teams are still operating as if the funnel begins at the form fill. It does not. It begins at the prompt. The teams that build a disciplined audit cadence on what their buyers are asking AI engines, and a content infrastructure designed to be cited rather than ranked, will own a structural advantage in this market for the next several years. The window on that advantage is open right now and closing fast.

Three Things You Can Do This Week

Here is what to actually do between now and Friday.

1. Run the Stakeholder Mirror Test on your last three closed-lost deals.

Pull the last three deals you lost in the final stages. For each one, list every stakeholder you know was involved. Then list every piece of your content, every LinkedIn post, every email, every webinar that stakeholder plausibly saw before the decision. If the answer for any stakeholder is “nothing,” that is your gap. If the answer is “two LinkedIn posts about our product features,” that is a worse gap. The goal is not attribution. The goal is to see, honestly, what version of you was in the room when you were not.

2. Write one piece this week that no one else in your category could have written.

Not a product post. Not a “five tips” post. One piece — eight hundred words is plenty — that takes a defensible position on something a hospital CFO is wrestling with right now. TEAM target price methodology. The HCAHPS digital transition. The cybersecurity insurance cliff. Site of service economics in your specialty. The test: if a competitor’s marketing team could have written it, do not publish it. If a CFO could forward it to their CEO without embarrassment, you are close.

3. Build one reusable piece of infrastructure, not another deliverable.

Pick one frame, one model, or one diagnostic that your buyers can use without you in the room. A four-question TEAM readiness self-assessment. A one-page worksheet that maps a service line’s HCAHPS exposure under the new methodology. A capital allocation lens for AI investments tied to specific reimbursement levers. Build it once. Put your name on it. Let it travel. The piece of paper that ends up on a CFO’s desk three months from now is worth more than thirty posts that get a polite like.

What I Can Offer That Most People Cannot

Over 25 years inside hospital operations means I read commercial content the way a CFO reads it — looking for whether the writer actually understands how the building works.

Here is what I am opening up to a small group of healthcare commercial teams this quarter:

The Hospital Buyer Content Audit. I will personally review up to ninety days of your outbound content — LinkedIn, email sequences, white papers, webinars, sales decks — and tell you, line by line, what a hospital CFO, COO, VP of Supply Chain, and value analysis chair would actually do with each piece. Read it. Forward it. Roll their eyes. Delete it. You will get a marked-up file, a one-page summary of what is working, what is invisible, and what is actively hurting you, and three specific pieces of infrastructure I would build first if I were running your commercial team.

This is not a content audit from a marketing agency. It is a buyer-side audit from someone who has sat across the table from your buyers for a quarter century.

The Hospital Buyer AI Search Audit. This is the companion offering, and for most teams it is the more urgent one right now. I will build a healthcare-specific prompt set tailored to your category and your buyer roles — CFO, COO, VP Supply Chain, value analysis chair, chief AI officer, clinical champion — and run it across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews under clean conditions. You will get a written report covering: where your brand is named and where it is invisible, where your domain is cited as a source and where competitors own the citation slots, where the AI is mis-describing what you do, which prompts are owned cleanly by a single competitor and why, the actual editorial board of your category (the domains the models trust most in your space right now), and a prioritized list of the specific content pieces and structural fixes I would build first to start moving the needle. This is the diagnostic almost no one in healthcare commercial has run yet, and the teams that run it first are the ones who will own the next several years of pre-sale visibility.

Both audits can be run separately or stacked. Stacked is the version I would push you toward, because the AI search audit tells you what your buyers are actually asking, and the content audit tells you whether what you are publishing answers it.

If you are interested in either one, message me directly on LinkedIn at https://www.linkedin.com/in/lisamiller at lisa@lisatmiller.com.

I am taking a limited number this quarter.

The Question Worth Sitting With This Week

If you sell into hospitals, the hardest question to sit with right now is whether the content you are producing would meaningfully sharpen the thinking of the executive you are trying to reach.

Not whether it is on brand. Not whether it shipped on schedule. Whether it would actually move them.

Most of what gets produced fails that test. The commercial teams that pass it are the ones building the next decade of pipeline.

If you want a deeper read on how this specifically plays out for medical device, life sciences, and healthcare technology companies, I wrote a longer companion piece on this earlier this year that is worth reading alongside this one: How Medical Device and Life Sciences Companies Can Use AI Search to Win Hospital Contracts in 2026.

— Lisa

The 5 Forces Behind Almost Every Hospital Decision

One of the things I love about selling to hospitals is that it rewards people who are willing to think deeply.

This is not a market where surface-level messaging wins for long. Hospitals are complex. The people leading them are balancing financial pressure, clinical priorities, operational realities, market dynamics, and constant change. That is exactly why the sales professionals who rise to the top are the ones who learn how to see the bigger picture.

Over the years, I found myself coming back to the same pattern. There were five forces showing up again and again behind hospital decisions. Once I began organizing my thinking around those forces, it changed the quality of my conversations, the kinds of questions I asked, and the way I helped clients position their solutions.

For high-performing salespeople, this framework is incredibly useful because it helps you move from presenting a product to understanding a decision.

Force 1: Alignment to payment models

If you sell to hospitals, one of the best investments you can make is learning how the organization gets paid.

That may sound basic, but in practice it is one of the biggest differentiators. The strongest salespeople do not stop at a high-level understanding of reimbursement. They study payment models closely enough to understand what those models are encouraging hospitals to do differently.

When CMS or Medicare introduces a new model or expands an existing one, it usually shifts priorities. It can change how hospitals think about coordination, outcomes, physician alignment, post-acute strategy, cost, and risk. In other words, it shapes what becomes important.

That is why this force matters so much. When you understand the goal behind the payment model, you can position your offer in a way that feels timely and relevant. You are no longer simply describing a solution. You are showing how your solution supports success in the environment hospital leaders are already navigating.

That is a much more strategic conversation, and hospital executives can feel the difference immediately.

Force 2: Alignment to regulations

The second force is regulation. While this one can feel technical, it is often one of the clearest paths to relevance.

Hospitals operate in a highly regulated environment, and those requirements influence urgency. Whether the issue is price transparency, cybersecurity, supply chain expectations, reporting obligations, or another compliance-related pressure, regulations have a way of moving priorities to the top of the list.

For salespeople, the opportunity is not to lead with fear. The opportunity is to lead with understanding.

When you can show that you understand what a new regulation means operationally, financially, or strategically, you become more credible. If your solution can reduce burden, simplify execution, improve readiness, or help a team respond more effectively, then you are contributing something that is genuinely useful.

That is an important distinction in hospital sales. The best messages do not just describe value in abstract terms. They connect directly to what leaders are being asked to manage right now.

Force 3: Alignment to aspirations

This is the force I believe people overlook most often, and yet it is one of the most human.

Hospitals are institutions, but decisions are still made by individuals. Those individuals have goals. They have milestones they are trying to hit. They have internal expectations, incentive plans, and career ambitions. They want to make progress. They want to be seen as effective. They want to lead important work well.

I saw this clearly years ago after speaking at a hospital association event. A finance leader approached me, and as the conversation developed, it became obvious that the opportunity was not only about helping the organization. He also wanted to grow into a CFO role. If he could bring in the right partner, create meaningful results, and be known internally as someone who drove change, that mattered.

That was such an important reminder. When you understand what success looks like for the person across from you, your conversations become more thoughtful and much more effective.

You begin asking better questions. What are you responsible for this year? What are you trying to improve? What would make this initiative meaningful for you and your team? Those are the kinds of questions that create trust.

And when you help your customer succeed as a person, not just as a title, you create a deeper kind of alignment.

Force 4: Alignment to competition

Hospitals are also far more competitive than many people realize.

They are competing for patients, physicians, service-line growth, reputation, market share, and strategic position. In many markets, leadership teams are constantly thinking about how to protect their strengths, where to grow, and how to become more differentiated.

That creates a very powerful opening for the right salesperson.

If your solution can help a hospital strengthen growth, improve access, protect referrals, enhance its reputation, or become more distinctive in the market, that should be part of your story. Sometimes what looks like an operational improvement on the surface has a much bigger strategic impact underneath.

I think this is especially important for people selling into highly competitive regions. Hospital leaders are not only trying to solve problems. They are also trying to build something stronger. They are trying to lead. They are trying to win in their market.

When you understand that, your message becomes more compelling because it connects not only to operational value, but to strategic ambition.

Force 5: Alignment to unique operational pressures

The fifth force is where strong salespeople really separate themselves.

Every hospital has unique pressures shaped by its community, geography, payer mix, local market conditions, service mix, and strategic activity. One hospital may be dealing with a high Medicaid population. Another may be preparing for hurricane season. Another may be expanding services, managing staffing constraints, or addressing a recent penalty or performance issue.

This is why research matters so much.

The most effective salespeople do not stop with the website or a short company profile. They look at public information, local news, strategic developments, filings, cost reports, community trends, and other signals that help them understand what that specific organization is managing.

When you do that work, you are able to ask questions that feel relevant and informed. You show up differently. You are not talking to a generic hospital profile. You are speaking to a real organization with real priorities at a specific moment in time.

That is often where momentum begins.

Why this framework matters

What makes this framework so effective is that it helps you think more expansively about alignment.

The strongest hospital sales conversations usually touch more than one force. A solution may support a payment model, ease a regulatory burden, and help an executive deliver on a key initiative. It may strengthen market position while also solving a local operational challenge. The more clearly you can connect your offer to what the hospital is already trying to accomplish, the stronger your positioning becomes.

That is why I believe this matters so much for high performers. It gives you a way to prepare better, ask smarter questions, and create more meaningful conversations with hospital leaders.

If you want to elevate how you sell to hospitals, start here. Study the forces shaping the decision before the decision is made. Learn what leaders are navigating. Learn what they are measured on. Learn what the market is asking of them. Learn what they are trying to build.

When you do that, you do more than improve your pitch.

You become the kind of sales professional hospital leaders want in the room.

Healthcare Sales Training That Translates CMS Policy Into Hospital Deals:

Fluent in Healthcare

Most companies believe their challenge is getting in the door with hospital executives. It is not. The real challenge is what happens next.

Access without strategy leads to stalled deals, endless follow ups, and opportunities that quietly disappear. The organizations that consistently win at the executive level do something fundamentally different. They understand the market at a deeper level, they bring a clear point of view, and they know how to guide a decision, not just present a solution.

This mini-book is about how to do that.

It is a practical framework for navigating complex hospital sales, where decisions are shaped by financial pressure, regulatory demands, and competing priorities across the organization. You will learn what it actually takes to get in front of the C Suite, how to structure your first interaction so it matters, and how to build a system that keeps deals moving forward instead of stalling.

If you are selling into healthcare, this is not about selling more. It is about selling differently, at the level where the most important decisions are made.

Inside this mini-book:

What It Really Takes to Get in Front of Hospital Executives

1. Know the market better than anyone in the room

2. Stand out by bringing a point of view

3. Orchestrate the first presentation like it is your only shot

Why Your Best Deals Keep Stalling and What to Do About It

Issue 1: There is no re engagement system
Issue 2: You have optimism without a strategy
Issue 3: You are missing the organizational dynamics

How to Know Where Your Deals Stand

The 5 Step C Suite Selling System

Step 1: Get clear on what you are selling
Step 2: Connect what you sell to what is happening in the market
Step 3: Elevate your message to the executive level
Step 4: Build sales materials and train the team to use them
Step 5: Build the system to prevent stalls before they start

C Suite Selling is not easy and that is the point

Introduction

Every sales leader has had a deal that’s been “in committee” for six months.

The story likely sounds something like this.

One of my clients had a significant multi-year, seven-figure deal on the line with a major health system. The CFO had reached out because they’d identified a gap, knew they needed help, and wanted a solution. My client’s on-site demonstration went well, as did meetings with multiple stakeholder groups. By every visible measure, the deal was moving forward.

Then, it stalled.

There was no dramatic objection or competing vendor announcement, just a gradual pause.

The health system’s responses took a little longer, and the team kept extending the timeline. Updates sounded reasonable, but nothing moved closer to closing. When we finally got to the bottom of it, the reason for the stall was simple: The health system decided to conduct an internal audit of its workflows before layering in a new solution.

This was completely reasonable, but also completely outside my client’s control.

So, the deal sat still for months while that process unfolded.

Stalled deals sound like a soft “maybe,” not a hard “no.”

A stalled deal isn’t a lost opportunity, but an absence of forward motion (with a plausible-sounding reason and a timeline no one can pin down).

The updates say the deal is in review, or that the slow timeline is part of the normal internal process. But with every passing week, the executive’s priorities shift a little further, and the momentum that took months to build drains away. At companies that sell medical devices, technology, and services to major health systems, this is not an edge case.

Between 40 and 60 percent of enterprise pipelines are stalled at any given time.

So, most sales organizations have learned to absorb that as a cost of doing business rather than as a problem to be solved.

I know this because I spent two decades on both sides of it—founding, growing, and successfully exiting a healthcare consulting firm that won against billion-dollar companies. Now, I work directly with the sales organizations to close the deals I used to be on the other end of.

The stalled deal problem is not a mystery. It’s a pattern, and it’s fixable.

The reason your deals stall is that you lack consistent, repeatable access to the C-suite and a system to move them forward.

Those two problems compound each other, and the result is a pipeline full of opportunities that should be closed and aren’t.

It’s worth being direct about what’s at stake.

The financial impact is the obvious part—stalled deals are unrecognized revenue, unmet growth mandates, and missed board commitments. For PE-backed companies operating on three- to five-year hold horizons, every significant stalled deal is a direct threat to the exit multiple. For publicly held companies, the effect on shareholder accountability is real and visible.

But there’s a less quantifiable cost that matters just as much: market credibility.

Landing a major health system is a signal. Consistently failing to close the enterprise deals your team has worked to develop is also a signal. Executives at peer health systems pay attention to these signals, as do boards.

For the sales team itself, the cost is personal. High-performing reps who can’t get consistent access or can’t close the deals they work hard to develop don’t stay forever. They go to a company where the system works. The organizational damage from that (in lost relationships, institutional knowledge, and team morale) is harder to recover from than any single stalled deal.

The deals that do close at the C-suite level open a different kind of opportunity altogether.

When a healthcare company becomes a trusted partner to a health system’s executive leadership, the relationship expands in ways that transactional deals never do. They lead to co-development opportunities, long-term contracts, and relationships that make the next enterprise deal easier to close. That’s what most companies are aiming for, but the path there runs directly through the stalled deal problem.

This mini-book is about what it takes to fix both C-suite access and stalled deals.

In the pages ahead, you’ll learn:

● What it takes to earn consistent C-suite access at major health systems and why most companies are approaching it wrong

● Why your most important deals keep stalling, and the three strategic issues that are almost always behind stalled deals

● How to diagnose where each stalled deal stands before it drifts too far to recover, and the five-step C-Suite Selling System that moves deals from stalled to signed

By the end, you’ll understand how to spot, unstick, and close stalled deals. You’ll get a framework for rethinking how your organization approaches C-suite access and deal velocity, built from my direct experience selling into (and now consulting for) some of the largest health systems in the country.

Let’s begin.

What It Really Takes to Get in Front of Hospital Executives

Too many healthcare sales leaders believe C-suite access is a volume game.

Sales reps just need to do more networking, send more cold emails, and focus on follow-up. Even worse, they assume their company’s brand name will open doors on its own.

Neither works at the executive level.

Hospital Chief Financial Officers, Chief Medical Officers, and Chief Clinical Officers are navigating one of the most complex operating environments in history. New CMS (Centers for Medicare & Medicaid Services) mandates, shifting reimbursement structures, tariff pressures, and institution-specific strategic priorities mean that every vendor relationship carries higher stakes than it did five years ago.

The vendors who earn their trust aren’t the ones who show up in their inbox most often. They show up knowing what’s at stake.

That’s why the most successful healthcare sales teams consistently do three things:

1. Know the market better than anyone in the room.

A hospital CFO fielding dozens of vendor outreach attempts every week has one filter that cuts through everything:

Does this person understand my world, or are they here to explain their product to me?

Surface-level industry knowledge is enough for a conversation with a department director or a mid-level administrator. It’s not enough for the boardroom. C-suite executives think at the level of institutional strategy, financial performance, and regulatory exposure. If a sales rep can’t speak that language with credibility, the meeting ends—politely, professionally, and without a follow-up.

Two recent CMS initiatives illustrate this gap.

The Rural Health Transformation (RTH) Program and the Transforming Episode Accountability Model (TEAM) initiative are both mandates that a significant percentage of health systems must now respond to. The health systems affected are actively working through the implications. Most vendors selling into those systems don’t know them well enough to be useful in that conversation.

As a sales rep, that knowledge is your opening.

It’s not because the information is secret. (It’s publicly available on the Medicare website, in CMS presentations, and in the audio recordings of policy briefings.) The opening exists because almost no one on the vendor side does the work to stay up to date on industry-specific information.

For example, I was recently giving a sales presentation to the Chief Medical Officer of one of the largest health systems in the country. The conversation turned to a specific CMS ruling about beneficiary incentives—how hospitals can now offer patients certain incentives tied directly to outcomes without it constituting inducement. The CMO wasn’t aware of it. But I was. That single moment shifted the entire dynamic of the meeting, moving it from a vendor pitch to an advisory conversation.

That is what genuine market knowledge does at the executive level.

You become useful in a way that nobody else in the room expects.

2. Stand out by bringing a point of view.

Hospital executives hear the same claims from dozens of vendors every month.

“We can help you save money, reduce risk, and improve outcomes!”

The language is nearly identical across companies, categories, and pitches. The vendors who get remembered (and called back) arrive with a unique perspective on the problem. This isn’t product claims repackaged as insights, but a genuine point of view:

● An insight the executive hasn’t considered

● A framing of a problem that changes the conversation

● A truth about their organization that they haven’t been able to see

Here’s an example of what this looks like in practice. In the purchased services category—vendor contracts and outsourced services—there’s a fundamental visibility problem that most hospital finance teams don’t know they have. Enterprise Resource Planning (ERP) systems capture what was paid. They don’t capture what was inside the invoice. With purchased services, there’s no purchase order line, SKU, or receiving record. Every rate, every unit count, every billed quantity lives inside the invoice document and nowhere else.

Finance only sees a total, and that total gets processed and paid.

Most healthcare CFOs are accountants by training who care deeply about the details. But they have no idea this visibility issue exists. Neither do their consultants and vendors, who work with the same aggregated spend data, like contract benchmarking and category comparisons. All of it relies on totals, instead of the actual line items where potential savings live.

You can’t save what you can’t see.

Almost nobody sees this issue. But this one POV—you can’t save what you can’t see—has opened more C-suite conversations than any amount of outreach or follow-up could have for my clients and me. Especially when delivered clearly, backed by specifics, and offered without hedging.

A point of view like that doesn’t come from a positioning exercise or a messaging workshop.

It comes from genuinely knowing the customer’s world and being willing to put in the hard work to root out the problem and design a different solution.

3. Orchestrate the first presentation like it’s your only shot.

The first sales presentation is where your deal either converts into a relationship or ends.

I’m a strong believer that this is the most underestimated moment in the entire sales process. Most companies treat it like a formality. Those who close enterprise deals treat it as a strategic asset.

Unfortunately, most first presentations go something like this: There are 10 people on the call, and the first 20 minutes are spent on company history (the founding story, team bios, and headcount). By the time the reason for the meeting surfaces, the executive has mentally checked out.

You earn or lose a room in the first 90 seconds.

C-suite leaders don’t wait for the second half of a deck to decide if a conversation is worth their time. They make that call almost immediately. And most presentations give them every reason to move on.

To earn the room, lead with the big idea.

Share the specific insight you uncovered, the problem that matters right now, or the thing that makes the executive lean forward.

Instead of saying “let me tell you about our company,” say “here’s what we’ve seen across health systems like yours, and here’s why it matters right now.” Give concrete examples, specific numbers, and actual situations over hypotheticals.

Here’s what that looks like in practice:

● With clients, I’ll often open with something like: “You’re evaluating implants on cost per case, but the real value is whether they enable procedures you’re not doing today.”

● Or: “You’ve invested in automation, but your teams are still doing manual work because the data isn’t connected where decisions are made.”

Neither of those is a product claim, but both changed the conversation immediately.

The executives I’ve most respected have done the same thing at scale.

Glen Tullman built Livongo on a single reframe: people with diabetes don’t want to be more engaged with their disease—they want to spend less time on it. That one line challenged the chronic disease management industry’s core assumption before he ever mentioned a product.

Gary Guthart, the CEO of Intuitive Surgical, never pitched the da Vinci system as a robot. His reframe was that the story wasn’t the cost of the equipment. It was the total cost of patient care, and how a well-run robotics program is often the most profitable thing a hospital runs. That shift, from capital expense to financial outcome, is what turned a $1.5 million piece of equipment into a C-suite conversation.

A reframe makes the executive see their situation differently and earns the room.

But earning the room is only half the job. The close of that first sales presentation matters just as much as the open.

● A team that ends with “let us know if you have any questions” has handed control of the relationship back to the buyer.

● A team that ends with a specific, low-friction request—”If you can share this particular data set, we’ll run an analysis and send you back your own numbers with our findings within two weeks”—has done something fundamentally different.

A request gives the executive a reason to stay engaged. So the next step is your responsibility, not the executive’s. Asking for something instead of waiting for something is often the difference between a deal that moves forward and one that stalls.

Getting C-suite access is step one.

Having consistent C-suite access is hard, and many sales teams never achieve it reliably.

But another important aspect of C-suite selling that often gets overlooked is that the quality of your pre-presentation work affects what happens after the meeting.

Companies that invest in deep market knowledge, a differentiated point of view, and a strong first presentation tend to see fewer stalled deals. When deals do stall, they recover faster because the executive already sees them as a trusted voice. This means re-engagement is a continuation of a relationship rather than a cold restart.

That said, deals can still stall when C-suite access is done well.

The executive goes quiet, and follow-up emails go unanswered. The pipeline update sounds the same as last week. A lot of sales organizations don’t have a clear explanation for why or a system for what to do about it.

Let’s fix that.

Why Your Best Deals Keep Stalling, and What to Do About It

A stalled deal rarely announces itself.

It tends to dissolve slowly, with each update sounding vaguely reasonable:

“It’s still in review.”

“We’re waiting on the committee.”

“They’re just slow. It’s a long sales cycle.”

All of these excuses normalize stalled deals. They’re accounted for in forecasts, explained away in pipeline reviews, and treated as an inevitable part of selling into large healthcare systems. The team rationalizes the situation enough that action feels premature.

By the time you recognize a deal as truly stalled, you’ve already lost meaningful leverage.

After working with healthcare sales organizations for decades, I’ve seen the same issues repeatedly stall deals. They’re not always apparent, and they’re rarely named directly. But they’re often misdiagnosed as timing problems, when they’re almost always strategy problems.

Here are the most common issues that lead to stalled deals:

Issue #1: There’s no re-engagement system.

Most re-engagement is an email: “Just wanted to see if there were any updates on your end.”

That kind of outreach creates no urgency and adds no value to the executive’s world. What unsticks a stalled deal is a specific, relevant reason that gives the executive cause to move forward.

I’m a big believer that the best re-engagement strategy isn’t reactive.

It starts during the first presentation, before a deal has any chance to stall.

As the meeting comes to a close, give a simple request: Send us one specific data set, and we’ll run an analysis and come back with our findings. This should be something the team can easily pull, like a canned report. You don’t want to make it too labor-intensive.

If a deal stalls, an early data exchange becomes the re-entry point.

An executive who went quiet three months ago will read an email that says, “Based on the preliminary analysis we ran on your data, we’ve identified $1.5 million in opportunity. This is a first pass. Once we begin the engagement, we expect it to be significantly more. Would you like to reconnect next week?”

Speculative claims from a vendor are easy to ignore. But you can’t argue with your own data.

A specific finding based on the hospital’s own numbers is invaluable for moving a deal forward.

Other re-engagement tools that work are thought leadership tied directly to a regulatory or competitive shift the executive is actively navigating, peer benchmarking that shows how comparable health systems have addressed the same challenge, and a well-timed prompt that reconnects the executive’s personal strategic goals to what your solution delivers.

Issue #2: You have optimism without a strategy.

Sales cultures are optimistic by nature.

That’s not a criticism—optimism is part of what makes a high-performing team function. But unchecked optimism about stalled deals is expensive. When the team believes a deal is still alive because the executive hasn’t said no, risks go unaddressed. Competitive activity goes unmonitored. The executive’s shifting internal priorities (budget cycles, leadership changes, or new initiatives that have displaced yours) don’t get surfaced in time to respond.

One of the most valuable shifts a sales organization can make is learning to ask:

What could go wrong here?

This is a proactive discipline, not a reason to catastrophize. If you know the risks, you can address them before they become deal-killers. If you don’t, you find out when it’s too late to do anything about it.

To do this, ask strong questions in every executive interaction.

Don’t ask: “How are things going?” Instead, ask: “What’s changed in your priorities over the last 60 days?” Not “are we still on track?” but “is there anything that could slow down the decision on your end?”

To do this well, you have to pay close attention to the competitive landscape. Because in healthcare, a vendor that’s moving while you’re waiting is the one that wins.

Issue #3: You’re missing the organizational dynamics.

Deals at the C-suite level stall because the buying environment inside a health system is genuinely complex.

There are:

● Committee structures that move slowly

● Multiple decision-makers with competing priorities

● Internal champions who may want the deal to happen but don’t have the organizational influence to push it forward on their own

To work through this, ask: Does our internal champion have what they need to advocate for this deal when we’re not in the room?

A healthcare executive who was enthusiastic in your presentation still has to sell the decision internally to peers, the board, and budget owners. If they don’t have a clear, concise way to explain the value (or if the ROI case isn’t defensible under scrutiny), the deal stalls in committee. It’s not because the executive changed their mind, but because they ran out of ways to communicate your value.

This is exactly what happened with the client I mentioned at the start of this book.

The deal had been progressing well—they gave a strong on-site demonstration, had productive meetings with multiple stakeholder groups, and got genuine executive interest. Then, the health system decided to conduct a thorough internal audit of its own workflows. It was the right decision for them, but it meant months of internal work they had to build from scratch.

So, our response was to offer something they could actually use.

We’ve reached out and said:

“As you’re auditing your own process, would you like to see how other hospitals have done the same? We definitely have a process and a framework that hospitals have used. Would this be helpful?”

Right away, they answered, “It would absolutely be helpful.”

They were essentially building the audit from scratch. My guess is that it was tough to even start the audit because they had to map it out. So this gave them a framework for how others have done it. It was in a really nice, very well-designed, very well-written document. They used it and absolutely loved it.

Most importantly, it helped them complete their audit and continue with my client in the process.

Soon, the stalled deal was unstuck.

The principle is the same one that runs through every effective re-engagement strategy: Be useful in a way no one else is. Don’t do this in a generic “we’re here if you need us” sense, but be specifically useful in the context of what the executive is working on (and worried about) right now.

How to Know Where Your Deals Stand

Not all stalled deals are the same.

Treating them as if they are is one of the most common and costly mistakes a sales organization can make. Understanding where a deal sits on the spectrum determines what you can still do about it. A useful way to think about this is a simple traffic light framework:

● Green zone: The deal is paused but warm. The executive is still reachable, the relationship is intact, and proactive re-engagement can accelerate it. These are your highest-leverage opportunities, and they should be treated as such.

● Yellow zone: The decision timeline is slipping. The risk of reprioritization or competitive entry is real. The window for easy recovery is closing, and what’s needed is a targeted re-engagement strategy—not another check-in.

● Red zone: The deal has stalled long enough that competition has entered, executive focus has shifted, and margin concessions start to look tempting. Recovery is difficult and expensive. Sometimes, the right answer is a graceful exit rather than a desperate push.

The traffic light framework is simple to use, but it requires an honest assessment that optimistic sales cultures aren’t always wired to do on their own. Most companies don’t have a system to diagnose which “zone” their deal is in. This means they apply the same tactics to a red-zone deal as a green one, and then wonder why nothing moves.

A simple starting point is to pull every deal in your pipeline that hasn’t moved in the past 30 days or more, assign each one a zone, and then look for patterns. Most sales leaders find the distribution more concerning than they expected. That’s often the moment when the stalled-deal problem stops feeling abstract.

Once you know where your deals get stuck, you can begin building the system to fix it.

The 5 Step C-Suite Selling System

The following five steps are as much a thought exercise as a framework.

As you work through them, keep your own company in mind. Notice when the answers come easily and when they don’t. These gaps often lead to stalled deals.

This is the process I developed over two decades of selling into health systems myself, and the same process I now use with clients to help them build consistent C-suite access and close the deals that matter.

The goal is to help you see your own commercial situation through a different lens.

Step 1: Get clear on what you’re selling.

Before messaging, deck design, or access strategy, you need a deep understanding of what you sell, where it fits in a health system’s world, and what problem it solves at the executive level.

This sounds obvious, yet it’s almost never clear.

A lot of companies can describe their products. Very few can articulate how it connects to the strategic priorities of a CFO, a CMO, or a Chief Clinical Officer. And fewer still can map it to what that specific executive is personally accountable for this year. There’s a significant difference between the two, and that difference determines whether you’re having a supply chain conversation or a C-suite conversation.

A spine company I worked with is a good example. They had been stuck selling to supply chain for years and had solid relationships at the department level, but no traction at the executive table. When we dug into what their product did, something different emerged: the technology enabled access to a net-new surgical population, patients who previously weren’t candidates for surgery at all.

That’s not a cost reduction story. That’s a top-line revenue story, and it’s a conversation for a CFO who has to report growth to the board. The product hadn’t changed, just the understanding of where it fit.

The questions to ask your own team:

● What is our flagship offering, and what is its highest-value application in a health system context?

● Who does it impact beyond the department that uses it directly (supply chain, reimbursement, operations, patient outcomes)?

● What does a health system executive have to believe to say yes, and do we have a clear path to helping them get there?

The companies that can answer these questions are the ones getting in front of the executive who can say yes.

Step 2: Connect what you sell to what’s happening in the market.

Once you understand your product in depth, the next step is to connect it to the external environment—the regulatory shifts, competitive pressures, and institutional priorities that shape executives’ decision-making right now.

Most companies do a version of this for their marketing materials.

That’s not what this step is about.

This is about your reps knowing the market well enough to teach it, not just to mention it. They have to walk into a CFO’s office and surface something the executive hasn’t seen or thought of yet. This requires staying on top of insights and industry trends.

Most companies won’t do deep industry research, which is exactly how you stand out.

For example, I discovered the TEAM Initiative—a significant CMS mandate—through a client engagement. I was working with a company that had a cardiac surgery product, doing a deep dive into everything their product touched. Through that research, I came across the TEAM program before most people in the market were talking about it. That knowledge became a differentiator not just in one meeting, but across multiple engagements where executives hadn’t yet mapped the mandate to their own operations.

That’s the level of market depth this step requires. It typically takes three to four weeks of focused research to build properly. In my experience, the companies that invest in this work show up to C-suite conversations with information nobody else is bringing. That changes the dynamic before you’ve said a word about your product.

You can ask these questions to pressure-test:

● What CMS or regulatory changes are directly relevant to what you sell, and do your reps know them well enough to explain the implications — not just name them?

● What is the competitive landscape inside the health systems you’re targeting, and are your real differentiators built into how the team sells or just into the product brochure?

● What are the specific strategic priorities of the systems on your target list, and how much of that is publicly available in annual reports, board presentations, or leadership interviews?

When you or your reps know something the executive doesn’t, the entire dynamic of the conversation shifts in your favor before you’ve said a word about your product.

Step 3: Elevate your message to the executive level.

Armed with product depth and market intelligence, the third step is translating that into a message that resonates specifically with C-suite leaders.

C-suite executives think in terms of strategic priorities, financial performance, competitive positioning, and institutional reputation. They are not looking for a product demonstration. They are looking for a perspective that helps them see their own situation more clearly, and a credible path to the outcomes they’re accountable for.

I’m a big believer in writing thought leadership directed at what a hospital CFO or CMO needs to know.

Don’t share generic industry content. Give a specific perspective on the decisions that are live for executives in that role right now. Directors and VPs below the C-suite will read it too, because they want to anticipate what their leadership cares about. You never lose by writing to the executive level. You always lose by writing below it.

The questions to work through:

● What are your genuine points of view that executives would find useful or surprising?

● What does a peer health system leader already know, and what can you tell them that they don’t? The gap between those two is where the conversation gets interesting.

● Does your message speak to the specific executive you’re meeting with (their role, accountabilities, and current strategic context), or is it the same message regardless of who’s in the room?

Step 4: Build sales materials and train the team to use them.

Strategy and messaging are only valuable if they translate into materials the sales team can use. This is where many organizations lose the work they’ve done in the first three steps.

There are two common failure modes.

The first is creating generic materials that can’t be customized to a specific health system or executive. The second is creating excellent materials and then failing to train the team on how to use them. So reps fall back on the familiar generic deck that wasn’t working in the first place.

Here’s what a well-built set of materials looks like in practice:

● A first presentation designed to open with the big idea and the executive’s priorities

● A follow-up sequence built to prevent stalls, including a specific data request that keeps momentum in the team’s court

● Custom data assets built around a specific health system’s own numbers, gaps, opportunities, and situation

● A train-the-trainer model: one internal expert who understands the strategy deeply enough to coach the broader team

Remember, the market is constantly changing. So you have to stay up to date on new mandates, competitive shifts, and executive priorities. The best engagements include a mechanism for keeping the materials current rather than treating them as a finished product.

Step 5: Build the system to prevent stalls before they start.

The most valuable work happens before a deal gets the chance to stall.

Companies that consistently close at the enterprise level build an orchestration system around every active deal. Consider this a relationship-management and re-engagement protocol that keeps the executive engaged while always keeping the ball in your team’s court.

This is where the bake-off strategy becomes relevant.

When I ran VIE Healthcare, I once competed against much larger firms for a significant five-year contract with a well-known health system. All three companies under consideration provided similar services, and the health system struggled to differentiate among them on paper. Instead of waiting for them to figure it out, I suggested a bake-off.

Give all three of us the same, small pilot project and see the work in real time.

I knew my competitors couldn’t move as fast as we could. We completed a thorough analysis with detailed findings in two weeks, while the other firms dragged it out. The health system didn’t need to rely on promises or presentations to make the decision. They’d seen the work.

We won the five-year contract.

Two years later, a different health system found itself in the same situation. I offered the same suggestion, and we got the same outcome.

The principle behind the bake-off is the same one behind the data request after the first presentation. Don’t wait for the buyer to figure it out. Give them a reason to move, and make that reason concrete.

The questions every deal team should be able to answer:

● What happens after the first meeting? What specific ask does the team make that keeps the next step on their plate rather than the buyer’s?

● What are the early warning signs that a deal is moving from the green to the yellow zone, and what’s the response plan when that happens?

● Does each executive in the buying process have what they need to advocate for the deal internally? What would make that easier for them?

Now, you can’t prevent every stalled deal. In a complex buying environment, some deals will stall regardless. The goal is to reduce them significantly, catch them early when they do occur, and never let a green-zone deal drift to red because no one was paying attention.

C-Suite Selling Is Not Easy, And That’s The Point

“This is not easy” is one of the first things I say to clients before we begin working together.

Selling to the C-suite at major health systems is among the most demanding tasks a healthcare sales organization can undertake. It requires a depth of market knowledge most teams haven’t built, a precision of message most pitches don’t achieve, and a level of orchestration—across access, positioning, first presentation, and post-meeting follow-through—that very few organizations have turned into a repeatable system.

That’s not a criticism of the people doing the work.

The sales leaders and commercial officers I work with are talented, motivated, and deeply committed to growing their companies. The problem isn’t effort. It’s that nobody handed them a system that works at this level, and building one from scratch while managing a pipeline, a team, and a board is genuinely hard.

But over two decades, I’ve consistently seen the companies that build this system close different deals. They get longer contracts, stronger partnerships, and relationships with health system executives that expand over time. Those companies stop competing on price because they’re no longer being evaluated the same way as everyone else.

The ones that don’t build the system keep absorbing stalled deals as a cost of doing business—until the missed growth mandates, the lost talent, or the pressure from a board or a PE timeline makes that no longer an option.

The path from where most companies are to where they want to be is not a mystery.

It’s a system, and it’s buildable.

The companies that create a C-suite selling system become the vendor that health system executives call when something important needs to get done.

If you recognize your company in any of these pages, the next step is a conversation.

I work with mid-market and enterprise healthcare companies to build the strategy, messaging, and systems that unlock C-suite access and close the deals that matter. My engagements are customized, intensive, and built around the specific commercial challenges of your organization.

To learn more, visit –

Lisa's website

Healthcare Sales Masterclass Training

Fluent In Healthcare Training

About Lisa T. Miller, MHA

Lisa T. Miller is a healthcare strategist, commercialization advisor, and former CEO of VIE Healthcare Consulting, a firm she founded in 1999 and grew into one of the Top 10 healthcare consulting firms in the United States. In 2022, VIE was acquired by Morgan Stanley Capital Partners.

Over a 30+ year career, Lisa has built a reputation for closing complex, high-value deals with hospital executives and helping organizations improve financial performance, operational efficiency, and patient outcomes. She developed a proven C-Suite selling framework that combines deep industry knowledge, education-based selling, and precise value articulation—enabling companies to access senior decision makers and secure multi-million-dollar engagements.

Lisa’s work is grounded in a rare dual perspective. She has spent decades inside hospitals advising CEOs, CFOs, COOs, and service line leaders on critical operational and financial decisions, while also building and scaling a national consulting firm that competed successfully against much larger organizations. This gives her a clear understanding of how healthcare organizations function—how decisions are made, where initiatives stall, and what drives action at the executive level.

In addition to her advisory work, Lisa has developed innovative technologies, including her patented Invoice ROI™ system, designed to uncover financial opportunities within complex healthcare spend. She was the host of “The Healthcare Leadership Experience” podcast, recognized as a top healthcare podcast by Feedspot, where she shares insights on margin improvement, operational strategy, and growth.

Today, Lisa advises healthcare organizations and companies that sell into healthcare on strategy, growth, and commercialization. Her focus is on helping leaders translate complexity into clear decisions, align solutions with what health systems value, and pursue opportunities that drive measurable impact.

She is the host of the podcast Selling to Healthcare and publishes a Substack Selling to Hospitals, where she shares insights on C-Suite selling, healthcare economics, and how companies can align with what health systems value.

There is a document published every year that tells you exactly what every hospital in your target market is being financially pressured about, which executives own those pressure points, and what the cost of inaction is — down to the dollar.

Most sales teams have never read it.

It is the annual CMS rulemaking cycle — the Federal Register updates, final rules, and program announcements through which the Centers for Medicare and Medicaid Services communicates the regulatory and financial environment that governs hospital operations. It is publicly available. It is free. And it contains more actionable intelligence about your hospital accounts than any market research report you will ever pay for.

The fluent seller reads it the way a financial analyst reads an earnings release — not for compliance purposes, not out of academic interest, but to identify where the pressure is building, which organizations are most exposed, and what the commercial opportunity looks like before the rest of the market figures it out.

The companies that have built this habit into their go-to-market motion do not chase deals. They position themselves ahead of the pressure and let the market come to them.

Here is the map.

Program One: HRRP — The Penalty That Never Goes Away.

The Hospital Readmissions Reduction Program has been penalizing hospitals since 2012, and it remains one of the most commercially significant CMS programs for companies selling into health systems — not because it is the largest program, but because it is the most visible, the most consistently discussed at the leadership level, and the one most directly tied to identifiable clinical and operational failures that vendors can credibly claim to address.

The mechanics are straightforward. CMS measures readmission rates for specific conditions — heart failure, heart attack, pneumonia, COPD, hip and knee replacement, coronary artery bypass grafting — and compares each hospital’s performance to a national benchmark adjusted for its patient population. Hospitals with excess readmissions receive a payment reduction on all Medicare discharges — not just the ones driving the readmissions, all of them — up to a maximum of three percent.

In a health system receiving $200 million in annual Medicare reimbursement, a three percent penalty is $6 million. That is not a line item. That is a strategic problem.

More than $550 million in penalties is distributed annually through this program. Roughly half of all hospitals in the country receive some penalty in any given year. The hospitals in the highest penalty tier are not obscure safety-net facilities — they are large, well-resourced regional systems with sophisticated leadership teams who are acutely aware of their readmission performance and actively looking for solutions.

What the fluent seller knows that the average rep does not: CMS publishes each hospital’s readmission rates and penalty status publicly every year. You can identify, before you ever make a call, exactly which of your target accounts are in the penalty tier, which conditions are driving their exposure, and how their performance compares to peer institutions. That is your opening. That is your reason for the call. That is the conversation that gets the meeting.

Program Two: VBP — The Two Percent That Focuses Every CFO’s Attention.

The Hospital Value-Based Purchasing program does something elegant and consequential. It takes two percent of every participating hospital’s Medicare reimbursement — withheld upfront — and redistributes it based on performance across four domains: clinical outcomes, safety, efficiency and cost reduction, and patient and caregiver experience.

Hospitals that perform above the national median get their two percent back plus a bonus funded by the penalties collected from underperformers. Hospitals that perform below the median get back less than they put in. The spread between the best and worst performers in a large health system can represent tens of millions of dollars annually.

This creates a very specific dynamic for sellers. Every hospital executive is aware of their VBP score. The CFO tracks it because it directly affects net reimbursement. The CMO owns the clinical outcomes domain. The CNO owns the patient experience scores, which carry significant weight in the program. The quality team owns the safety metrics. And the CFO wants all of them to own their numbers, because the aggregate performance determines whether the hospital is a net receiver or a net payer in the redistribution.

If your solution improves clinical outcomes, reduces preventable harm events, or drives better patient experience scores, you have a direct line into this program. The fluent seller does not just say their solution improves quality. They say it in the specific language of the VBP domain it addresses, with reference to how the scoring methodology works and what a meaningful improvement in that domain is worth in recovered reimbursement. That is a different pitch entirely.

Program Three: TEAM — The Bundled Payment Mandate That Is Reshaping Surgical Sales.

The Transforming Episode Accountability Model is the most consequential CMS development for companies selling into surgical service lines in the current environment, and it is still underappreciated by the majority of sales teams operating in that space.

Here is what TEAM does. For hospitals selected to participate — and participation is mandatory, not voluntary — CMS bundles the payment for an entire surgical episode into a single target price. The episode begins at admission and extends ninety days post-discharge. If the hospital’s actual costs across that entire episode come in below the target price, they keep the difference. If they exceed the target, they pay back the overage.

The implications for purchasing decisions are significant. Under a traditional fee-for-service model, a hospital is mostly accountable for what happens during the inpatient stay. Under TEAM, they are accountable for everything that happens in the ninety days after the patient leaves — readmissions, skilled nursing facility stays, home health utilization, outpatient visits, complications that require additional intervention. The entire post-acute cost picture is now the hospital’s financial responsibility.

This changes the conversation around surgical technology, care coordination, patient monitoring, post-discharge engagement, and every other category that touches the surgical patient journey. Products and services that could previously be evaluated on their standalone clinical merits are now being evaluated on their contribution to episode cost and outcome — a broader, more financially sophisticated frame.

The company that walks into a surgical service line conversation knowing the hospital’s current TEAM performance data, understanding which episode types are creating the most cost variance, and articulating how their solution affects the ninety-day cost picture is in a categorically different conversation than the one leading with clinical features. That is the TEAM opportunity. It is open right now and most of your competitors are not yet speaking the language.

Program Four: ACCESS — The Ten-Year Wave Most Sellers Are Missing.

The Achieving Comprehensive Care for Existing Serious Symptoms program — ACCESS — is a chronic care model that covers approximately two-thirds of the Medicare population and is designed to transform how hospitals and health systems manage patients with complex, ongoing conditions over a ten-year horizon.

The commercial relevance of ACCESS is different from the penalty-driven urgency of HRRP or the bundled payment accountability of TEAM. ACCESS creates a long-horizon investment thesis. Health systems that are serious about performing well under this model are making structural changes to how they identify, engage, and manage high-risk patients across their entire population — changes that require technology, care management infrastructure, data analytics capability, and clinical workflow redesign.

For companies selling care management platforms, patient engagement tools, analytics solutions, or chronic disease management programs, ACCESS is not a single sales conversation. It is a market-shaping event. The health systems that take it seriously are not looking for a vendor. They are looking for a partner capable of thinking across a ten-year performance horizon.

The fluent seller understands that ACCESS conversations happen at a different altitude than HRRP conversations. They are not about avoiding a penalty this year. They are about building a care delivery capability that performs under a model that will govern two-thirds of Medicare reimbursement for the next decade. That is a board-level conversation. It is a CEO conversation. It is the kind of conversation that does not happen unless the seller demonstrates they understand the model at the depth required to be credible at that level.

Program Five: Rural Health Transformation — The $50 Billion Market Most Sellers Have Not Found Yet.

Rural hospitals operate in a different financial and regulatory universe than their urban and suburban counterparts. Lower patient volumes, higher rates of uninsured and Medicaid patients, older physical infrastructure, persistent workforce shortages, and thin or negative operating margins characterize much of rural healthcare in the United States. CMS has recognized that the standard payment models designed for high-volume urban health systems do not work for rural providers, and it has responded with a $50 billion investment in rural health transformation that is reshaping what rural hospitals can access, afford, and prioritize.

The Rural Emergency Hospital designation, value-based payment models adapted for rural providers, and targeted investment programs for critical access hospitals create a wave of purchasing activity in a market segment that most healthcare sales organizations have systematically underinvested in — because the per-deal size looked smaller and the sales motion looked harder.

Both of those assumptions are wrong. Rural health systems are making purchasing decisions right now, backed by federal investment, in categories where the competitive landscape is far less crowded than in urban markets. The sellers who understand the specific rural health regulatory environment — who can speak to critical access hospital financing, the Rural Emergency Hospital model, and the specific CMS programs designed for this market — are finding that their fluency creates an almost immediate competitive advantage in accounts where most vendors have never shown up prepared to speak the language of the room.

Program Six: IOTA — The Upside Most Transplant Programs Do Not Know They Are Leaving.

The Increasing Organ Transplant Access model creates financial incentives for kidney transplant centers that expand access, improve outcomes, and reduce waitlist mortality. Participating centers that hit performance targets can receive up to $15,000 per case in upside payments — a significant number for programs performing hundreds of transplants annually.

IOTA is a narrower program than the others in terms of the hospital population it affects, but for companies selling into transplant programs — surgical devices, immunosuppression management platforms, post-transplant monitoring solutions, organ procurement technology — it is the most directly relevant regulatory context for every conversation with a transplant program director, medical director, or CFO overseeing the transplant service line.

The fluent seller in this space does not walk in and talk about improving transplant outcomes in the abstract. They walk in and talk about IOTA performance targets, the specific metrics that drive upside payments, and how their solution moves the needle on those metrics in ways that are measurable and documentable. That is a conversation about revenue. That is a conversation that gets immediate executive attention.

How to read a CMS update like a sales intelligence report.

Every time CMS publishes a new rule, proposed rule, or program update, there is a standard set of questions a fluent seller asks.

Which hospitals are affected, and which of my target accounts are in that group? What is the financial exposure — what does a hospital at the median level of performance stand to lose or gain? Which executive inside the hospital owns the performance metric this program measures? What does this program require hospitals to do differently, and where does that create a need my solution addresses? And what is the timeline — when do the new requirements take effect, when do penalties begin, and when does the window for proactive investment close?

Those questions, applied to every significant CMS announcement, turn the Federal Register from a compliance document into a prospecting calendar. You know, months in advance, which conversations you need to be having, with which executives, at which organizations, and with what message.

That is not a sales advantage. That is a category advantage. And it compounds every quarter you sustain it while your competitors are still showing up with pitch decks about the shift to value-based care.

THE FLUENCY MOVE

Go to the CMS website and download the most recent HRRP penalty data for the hospitals in your primary market. Identify the three accounts in the highest penalty tier. For each one, note the specific conditions driving their excess readmission rates. Now write one sentence — just one — that connects your solution to that specific condition in the language of the penalty program. If you can write that sentence cleanly, you are ready to make the call. If you cannot, you have found the next gap to close.

This is Part 4 of the series.

Read the previous articles:

You can bring Fluency in Healthcare to your company -

fluentinhealthcare.com

When a hospital CFO tells you the timing is not right, she is not talking about your timeline.

She is talking about five separate conversations happening simultaneously in five separate directions — up to her board, out to her bondholders, across to her accreditation body, down to her operating executives, and sideways to CMS — all of which have to align before a single major purchasing decision can move. Your deal is not stalled because she is busy. It is stalled because you have not yet connected what you are selling to the pressure any of those five conversations are generating.

Most sales teams know about one of the five bosses. They know about the internal hierarchy — the committee, the department head, the C-suite sign-off. They build their sales strategy around navigating that structure. They map the org chart. They find the champion. They work the internal politics.

And they wonder why it still takes fourteen months to close.

The org chart is not the decision architecture. The five bosses are.

Boss One: The Centers for Medicare and Medicaid Services.

CMS does not have an office in the hospital. It does not attend leadership meetings or show up on any org chart. But it is the most influential force in every major purchasing decision a hospital makes, and the sales teams that understand this have a fundamental advantage over every team that does not.

Here is how it works.

CMS sets the reimbursement rules that determine how much revenue a hospital receives for the care it delivers. It sets the quality metrics that determine whether that revenue is enhanced or penalized. It designs the payment models that decide whether a hospital is accountable for costs and outcomes across an entire episode of care or just the inpatient stay. Every time CMS updates a program, adjusts a penalty calculation, or introduces a new payment model, it changes the financial calculus that governs what hospital executives can afford to prioritize, invest in, and buy.

This means that every significant product or service a hospital purchases is evaluated, at some level, against one question: how does this help us perform better under the payment models and quality programs CMS has put in place?

If your solution helps a hospital reduce readmissions, it speaks to HRRP. If it improves surgical episode efficiency, it speaks to TEAM. If it drives quality metric performance, it speaks to VBP. If you cannot articulate which CMS pressure your solution addresses — in specific, quantified terms — you are asking the hospital to make a purchasing decision that lacks regulatory justification. And purchasing decisions without regulatory justification do not get approved. They get deferred.

The fluent seller treats CMS as the first audience for every message they craft. Not the CFO. Not the CMO. CMS. Because if the message holds up against the regulatory logic CMS has established, every conversation downstream becomes easier.

Boss Two: The Bond Market.

This is the boss most sales teams have never thought about at all, and it explains more about hospital purchasing behavior than almost anything else.

Most hospitals in the United States are nonprofit organizations that finance their capital needs — new facilities, major equipment, technology infrastructure — through municipal bonds. Their ability to borrow at favorable rates depends on their credit rating. Their credit rating depends on their financial performance. And their financial performance is scrutinized by rating agencies — Moody’s, S&P, Fitch — that pay close attention to operating margins, days cash on hand, debt service coverage ratios, and the regulatory environment those metrics are exposed to.

What this means in practice is that a hospital CFO is managing not just an operating budget but a credit profile. A deteriorating operating margin does not just create a budget problem. It creates a borrowing problem. A borrowing problem constrains the capital available for facility investment, technology replacement, and program development. A constrained capital position affects the hospital’s ability to compete for patients, physicians, and staff — which feeds back into revenue, which feeds back into the credit profile.

This is why hospital executives are so attuned to margin. It is not just about the current year’s budget. It is about the cost of capital for the next decade.

When your solution helps a hospital protect or improve its operating margin — by reducing penalty exposure, improving reimbursement performance, or lowering operational costs — you are not just solving a budget problem. You are speaking to the credit profile. That is a different conversation. That is a conversation that gets a CFO’s full attention.

Boss Three: The Accreditation Body.

The Joint Commission, DNV Healthcare, the Healthcare Facilities Accreditation Program — hospitals are accredited by independent bodies that evaluate their performance against defined standards for patient safety, care quality, and operational integrity. Accreditation is not optional. Without it, a hospital cannot participate in Medicare and Medicaid. Losing accreditation is an existential event.

Accreditation surveys happen on a cycle — typically every three years, with the possibility of unannounced visits in between. The period leading up to a survey is one of the most operationally intense times in a hospital’s calendar. Leadership attention narrows sharply. Discretionary projects get paused. Vendor conversations that are not directly connected to survey readiness get deprioritized.

The sales team that does not know where its target accounts are in their accreditation cycle will repeatedly schedule meetings at the wrong time and wonder why engagement is low. The team that tracks accreditation timelines knows exactly when to lean in and when to wait — and knows how to frame their solution in terms of accreditation standards when the timing is right.

More importantly, accreditation standards create a vocabulary that hospital quality and compliance leaders speak fluently. If your solution addresses infection control, medication management, patient rights, or any other accreditation domain, there is a specific regulatory language your team should be using in those conversations. Not the general language of quality improvement. The specific language of the standard.

Boss Four: The State Health Department.

The federal regulatory layer gets most of the attention, and rightly so — CMS is the dominant force. But state health departments exercise significant authority over hospital operations, and that authority varies meaningfully from state to state in ways that affect purchasing decisions.

Certificate of Need laws, which exist in roughly half of US states, require hospitals to obtain state approval before making major capital investments in new facilities, services, or equipment. This means that a purchasing decision that would take six months in a state without CON requirements might take eighteen months in a state where it does — not because of internal politics, but because of a regulatory approval process your sales team may not even know exists.

State Medicaid programs, which are administered jointly by states and CMS, have their own quality requirements, managed care structures, and reimbursement rules that layer on top of the federal framework. In states with large Medicaid populations, these state-level rules can be as consequential as the federal ones.

State health departments also conduct their own inspections and licensing activities, with their own calendars and compliance demands. A hospital that is navigating a state inspection cycle is in a similar position to one approaching a Joint Commission survey — leadership bandwidth is constrained and discretionary vendor engagement drops.

The fluent seller knows the regulatory environment of the specific states where their target accounts operate. They know whether CON laws apply, what the state Medicaid structure looks like, and whether any active state health department activity is affecting their accounts’ leadership attention.

Boss Five: The Board.

The hospital board is the governance structure that every CEO ultimately answers to. In nonprofit health systems — which represent the majority of US hospitals — the board includes community leaders, physicians, business executives, and other stakeholders who provide oversight of the organization’s strategic direction, financial performance, and mission alignment.

Board priorities shape executive priorities. If the board has made a strategic commitment to expanding behavioral health services, the CEO and CFO are going to have behavioral health on their agenda in a way that was not there before. If the board is concerned about the organization’s financial trajectory, the CFO’s tolerance for new spending will be lower and the standard of proof required for any major investment will be higher. If the board has adopted a strategic plan with specific goals around quality, access, or community benefit, those goals become the filter through which every significant organizational decision gets evaluated.

Board meetings happen on a schedule — quarterly in most systems — and board reporting creates internal deadlines that shape when executives are available for external conversations and when they are not. The week before a board meeting, a CFO is preparing her financial report. The week after, she is managing action items. The weeks in between are when the real strategic conversations happen.

The sales team that understands the board’s current priorities, and can connect their solution to those priorities, is speaking to the governance layer — the highest level of the decision architecture. That is a different kind of conversation than anything that happens in a procurement review.

How the five bosses work together.

These five forces do not operate independently. They interact, and the interactions create the specific combination of pressures that is shaping your target account’s decision-making right now.

A hospital facing a CMS penalty under HRRP is also managing the impact of that penalty on its operating margin, which affects its credit profile with the bond market, which the board is monitoring, while simultaneously navigating a Joint Commission survey cycle in which readmission rates are a quality indicator, all within a state regulatory environment that may or may not constrain how quickly they can invest in a solution.

That is the actual context of the deal you are trying to close.

The sales team that maps this landscape for each target account before the first conversation is operating in a different world than the team that shows up with a pitch deck and a product demo. They know which pressure is most acute right now. They know which boss is loudest in the room. They know how to frame their solution so it speaks to the pressure that is already driving the conversation at the leadership level.

That is not sophisticated sales technique. That is fluency. And it is learnable.

The mapping exercise that changes everything.

Before your team makes another call to a hospital account, have them answer five questions.

What CMS programs is this health system currently enrolled in, and what are their performance levels on the metrics those programs measure? What is their publicly available financial profile — operating margin, days cash on hand, bond rating if available? When were they last accredited, and when is their next survey cycle likely to occur? What state regulatory environment do they operate in, and are there any active state health department activities affecting them? And what do you know about their board’s current strategic priorities, either from public statements, strategic plans, or annual reports?

If your team cannot answer those questions before a first meeting, they are walking into the conversation without a map. The executive on the other side of the table has been living in that landscape every day for years. The fluency gap opens in the first five minutes — when the rep asks a question that reveals they have not done this work.

The good news is the information is available. CMS publishes performance data on every hospital in the country. Financial data is publicly available for nonprofit health systems through their 990 filings. Accreditation status is public. State regulatory information is accessible. Board priorities are often articulated in annual reports, community benefit statements, and strategic plans that hospitals publish for exactly this purpose.

The fluent seller uses this information not as background research that informs the pitch, but as the foundation of the conversation itself. They walk in already knowing which boss is loudest in the room. And they start talking about that boss before the executive has to bring it up.

That is the moment the executive stops seeing a vendor and starts seeing a peer.

THE FLUENCY MOVE

Pick your single highest-priority target account. In the next 48 hours, find the answers to all five questions above using only publicly available information — CMS data, the organization’s 990 filing or audited financials, Joint Commission accreditation status, state health department records, and the health system’s most recent strategic plan or annual report. Write a one-page brief on which of the five bosses is currently loudest for this account. Bring that brief to your next internal account review instead of a pipeline update. The conversation your team has will be different from any account conversation you have had before.

You can bring Fluency in Healthcare to your company -

fluentinhealthcare.com

This is Part 3 in the Series -

Here are Parts 1 & 2

Learn more about Lisa’s work at: Lisa T. Miller

Every year, thousands of healthcare sales teams sit through the same training.

They learn about active listening. They learn about challenger selling and SPIN methodology and how to navigate a complex buying committee. They learn about building rapport and asking open-ended questions and the importance of a strong follow-up cadence. Some of them learn about value-based care, in a general, conceptual way — the kind of way that lets a rep say we understand the shift to value without being able to explain what HRRP stands for or how a bundled payment actually flows through a health system’s P&L.

Then they go back into the field and lose deals to competitors who can.

The sales leader looks at the results and concludes the team needs more training. So the cycle repeats. More methodology. More roleplay. More pipeline reviews. The win rate does not move. The average sales cycle stays somewhere between nine and fourteen months. The deals that close close because of a champion, not because of the team’s ability to operate at the C-suite level.

This is not a training problem.

It has never been a training problem.

What training solves and what it cannot.

Training solves execution problems. If your rep does not know how to run a discovery call, train them. If they are not following up consistently, build a cadence. If they are pitching too early, coach the sequence. These are real problems and training is the right tool.

But training cannot solve a category problem. And the fluency gap is a category problem.

Here is what that means.

A category problem exists when the market does not yet have language for the problem you solve — or worse, when the market has the wrong language, which causes buyers to sort you into a box you do not belong in. When that happens, no amount of pitch refinement helps, because the issue is not how you are communicating your value. The issue is that the frame your buyer is using to evaluate you is the wrong frame entirely.

Most companies selling into hospitals have a category problem that looks like a sales problem. Their reps are being evaluated as vendors — commodity providers competing on price, relationships, and feature checklists — when they should be entering the conversation as strategic partners to an executive managing federal regulatory pressure. The difference between those two positions is not a matter of how well the rep delivers their pitch. It is a matter of which conversation the rep is even capable of being in.

You cannot train your way from vendor to strategic partner. You have to change the category you occupy in the buyer’s mind. And the only way to do that is to demonstrate, consistently and fluently, that you understand the buyer’s world at a level that makes you useful before the RFP ever gets issued.

The company that names the problem owns the solution.

This is the core principle of category design, and it applies directly to healthcare sales.

Every major shift in how hospitals buy things was preceded by someone naming a problem that the market did not have clear language for yet. When CMS introduced the Hospital Readmissions Reduction Program, it did not just create a financial penalty. It created a named problem — readmission risk — that every hospital suddenly needed a solution for. The companies that moved first to own the language around that problem, to become the authoritative voice on what caused readmissions and what fixed them, captured the category. The ones that showed up later with readmission reduction solutions competed on price.

The same dynamic plays out at the company level. The sales organization that teaches its team to speak in the language of hospital executives — that builds content, frameworks, and conversations around the specific financial and regulatory pressures those executives face — is not just closing more deals. It is designing the category around its own expertise. It is making itself the reference point for a problem the market already has but may not yet have named clearly.

That is a fundamentally different position than being a good vendor.

Good vendors get evaluated. Category leaders get called.

What fluency actually is.

Let me be specific, because this word gets used loosely and it should not.

Fluency is not familiarity. A rep who has been selling into hospitals for ten years and has sat through a hundred leadership meetings is not automatically fluent. Familiarity means you have been in the room. Fluency means you understand what the room is actually about.

Fluency is not vocabulary. Knowing that HRRP stands for Hospital Readmissions Reduction Program is not fluency. Being able to sit across from a CFO and explain precisely which of her DRGs are driving her penalty exposure, and then connect that exposure to a conversation about your solution’s documented outcomes — that is fluency.

Fluency is not enthusiasm for healthcare. Some of the least fluent sellers I have encountered care deeply about the mission of healthcare. Caring is not the same as understanding. The executive on the other side of the table does not need you to believe in what they do. They need you to understand the financial and regulatory environment they are operating in.

Fluency is operational comprehension. It is the ability to walk into any hospital in the country and, within the first ten minutes of a conversation, identify which CMS programs are creating pressure for that organization, which executives own those pressure points, and what a credible solution narrative sounds like in their language. It is the ability to read the room not just emotionally but structurally — to understand why this CFO is asking that particular question, what is driving the concern underneath it, and what answer would move the conversation from evaluation to engagement.

That is a learnable capability. But it is not learned in a sales training. It is built through sustained, structured immersion in how hospitals actually work.

The $100 million company that keeps losing to the scrappy competitor.

I have seen this story play out more times than I can count, and it never stops being striking.

A large, well-resourced company — strong product, credible team, solid market position in adjacent sectors — decides to go after hospital accounts. They hire a VP of Sales with healthcare experience. They build a dedicated sales team. They develop a pitch deck that includes a slide about value-based care and a reference to CMS reimbursement trends. They invest in a CRM, a SDR team, a content marketing function. By every conventional measure, they are well-prepared.

They keep losing deals to a smaller competitor that has a fraction of their resources and a product that, on paper, should not be beating theirs.

The difference is almost always the same thing. The smaller competitor’s team can walk into a hospital leadership conversation and talk about TEAM bundled payments, HRRP penalty tiers, and operating margin compression in the same sentence, with the same fluency that the hospital’s own finance team uses. The larger company’s team has a slide about value-based care. The smaller company’s team has a conversation about the specific problem on the CFO’s desk this quarter.

The larger company diagnoses this as a sales effectiveness problem and schedules more training. The smaller company keeps winning.

This is the fluency gap expressing itself at the competitive level. And it compounds, because every deal the fluent competitor wins makes them more credible in the market, earns them more references, and deepens the category position they are building — while the larger company keeps wondering why their superior resources are not converting into superior results.

The category shift that changes everything.

Here is what happens when a company makes the transition from fluency-as-aspiration to fluency-as-practice.

The conversations change. Not incrementally — fundamentally. Executives who previously scheduled thirty-minute vendor evaluations start scheduling ninety-minute strategic conversations. Deals that used to stall in committee start moving because the executive sponsor has enough confidence in the seller’s grasp of the problem to push them through. The sales cycle compresses not because the team got better at following up, but because the time required to build credibility has been dramatically shortened. Credibility that used to take six months of relationship-building to accumulate now arrives in the first meeting, because the rep shows up already speaking the language.

The referral pattern changes too. Hospital executives talk to each other constantly — at conferences, in peer groups, in the informal networks that exist in every health system market. When a rep shows up in a conversation having already demonstrated genuine fluency, the executives in that room do not just evaluate them for their own accounts. They mention them to their peers. The rep becomes known in the market as someone worth talking to — not because they are likable, though that helps, but because they are useful at a level that is rare.

And the competitive dynamic shifts. Once your team is known as the team that actually understands how hospitals work, you stop competing on features. You stop competing on price. You stop competing on relationships, which are fragile and person-dependent. You compete on something much more durable — the demonstrated expertise that makes your company the obvious choice for any executive who wants a partner rather than a vendor.

That is the category shift. And it starts not with a sales methodology but with a decision to take fluency seriously as a strategic capability rather than treating it as a nice-to-have that good reps develop on their own over time.

The Fluency Gap is a leadership decision.

Here is the thing most sales leaders do not want to hear.

The fluency gap in your organization is not your team’s fault. It is yours.

Your team is selling the way they were hired to sell, trained to sell, and incentivized to sell. If the system they are operating in rewards activity metrics, product pitches, and short-cycle wins over the slower, harder work of building genuine market expertise, they will optimize for activity metrics, product pitches, and short-cycle wins. That is rational behavior.

Closing the fluency gap requires a decision at the leadership level — a decision to invest in building a team that understands healthcare at a depth that most of your competitors have decided is not worth the effort. It requires changing what you measure, what you train, what you hire for, and what you reward.

It requires deciding that fluency is not a feature of your best rep. It is the operating standard for your entire team.

That decision is available to you right now. The chapters that follow will show you exactly what it looks like to act on it.

THE FLUENCY MOVE

Sit in on the next three calls your team makes to hospital executives. Do not coach the pitch. Just listen for the moment when a CMS program, a quality metric, or a regulatory term comes up — from either side. Note whether your rep can engage with it fluently or whether the conversation pivots back to the product. That pivot is your data. Count how many times it happens across three calls and you will have a precise measurement of where your fluency gap starts.

You can bring Fluency in Healthcare to your company -

https://fluentinhealthcare.com

If you missed Part 1 - Start Here:

There is a meeting happening right now in a hospital somewhere in this country.

A CFO, a CMO, and a VP of Supply Chain are sitting around a conference table. They are not talking about your product. They are talking about a CMS penalty notice that arrived last Thursday. They are talking about what happens to their operating margin if their readmission rate does not move by Q3. They are talking about the TEAM model going mandatory next year and what that means for their orthopedic service line.

Your competitor’s rep is in that meeting.

Not because their product is better than yours. Not because they outpriced you, outmaneuvered you, or got there first. They are in that meeting because when the CFO mentioned HRRP six months ago, your rep nodded politely and pivoted back to the product demo. Their rep stopped, asked a very specific question about which DRGs were driving the penalty, and spent the next twenty minutes sounding less like a vendor and more like someone who had sat on the other side of that table.

That is the only difference.

This is not about sales tactics. It is not about closing techniques, account mapping, or how to get past the gatekeeper. There are enough written about those tactics and strategies. This is about something more fundamental — the gap between companies that sell into healthcare and companies that are trusted by healthcare. The gap between being heard and being taken seriously. The gap between having a great product and actually winning the deal.

That gap has a name.

It is called fluency. And most companies selling into hospitals do not have it.

I spent thirty years on the inside of healthcare — managing budgets, evaluating vendors, sitting in the meetings where the real decisions get made. I have seen extraordinary products lose to mediocre ones because the seller could not speak the language of the executive in the room. I have watched sales teams spend twelve months in a sales cycle that should have taken four, because no one on the team could connect their solution to the right pressure point at the right level of the organization.

I am writing about this because it is a solvable problem. Not through a one-day training. Not through a glossary of healthcare acronyms stapled to the back of your sales playbook. Through a genuine, structural change in how your team understands the market it is operating in.

Fluency is not about memorizing acronyms. It is not about putting your team through a compliance training module or adding a ‘regulatory insights’ slide to your pitch deck.

Fluency is about understanding how hospitals work — how they make money, how they lose it, who they answer to, and what keeps their executives awake at three in the morning. When you understand that, something remarkable happens. The conversation changes. The room changes. You are no longer a vendor presenting features. You are a peer presenting solutions to problems the executive already knows they have.

That is the moment deals get made.

The companies that figure this out first will win a disproportionate share of every market they compete in. The ones that do not will keep sending proposals into procurement portals and wondering why nothing is moving.

The market has already decided which kind of company wins in healthcare.

The question is which side of that line you are on.

This substack is Part 1 of a series on this strategy.

Lets begin -

You Are Not Selling to a Hospital. You Are Selling to a Balance Sheet Under Federal Pressure.

Here is something the hospital will never tell you.

When your rep walks in for that first meeting, the executive on the other side of the table is not thinking about your product. They are thinking about a number. Sometimes it is a readmission rate. Sometimes it is an operating margin that has been shrinking for eighteen months. Sometimes it is a CMS penalty they already know is coming and have not yet told their board about. Whatever the specific number is, it sits behind every question they ask, every objection they raise, and every reason they give for why the timing is not right.

Your rep is selling a product. The executive is managing a crisis.

Those two conversations almost never meet — and that is the entire problem this book exists to solve.

The hospital your rep visits is not the hospital that makes decisions.

Walk into almost any major health system in this country and you will find two hospitals occupying the same building.

The first hospital is the one your sales team can see. It has departments and service lines and administrators with titles and org charts and procurement portals. It has a clinical champion who loves your product and a supply chain director who wants three competing bids. It has a budget cycle that starts in September and a committee that meets on the third Tuesday of every month. This is the hospital most sales teams are trained to navigate. This is also the hospital where deals go to stall.

The second hospital is the one that actually makes decisions. It runs on federal reimbursement rules, quality metrics, penalty calculations, and bond covenants. Its real leadership team includes the Centers for Medicare and Medicaid Services, its accreditation body, its bondholders, and its state health department — none of whom show up on any org chart your sales team has ever seen. Every major purchasing decision in this hospital gets filtered through one question before it reaches any other: does this move our numbers in a direction that keeps us viable?

The executives who run this hospital are not being difficult when they slow-walk your deal. They are being rational. They are managing an organization that answers to more bosses than almost any other institution in the American economy, operating on margins that would shut down most businesses in other industries, under regulatory frameworks that change every year and carry eight-figure financial consequences when organizations get them wrong.

Until your team understands that hospital — the real one — you are not in the conversation.

The morning the penalty notice arrives.

Let me show you what I mean.

It is early October. A CFO at a regional health system opens her email and finds the annual Hospital Readmissions Reduction Program update from CMS. The notice tells her that her system’s readmission rate for heart failure patients puts them in the penalty tier for the coming fiscal year. The penalty is $2.3 million — not catastrophic, but still very serious. Even for a system already running a 1.8 percent operating margin, where a $2.3 million penalty does not just affect the budget — it affects what gets delayed, what gets cut, and who has to explain it to the board. She has until her board meeting in six weeks to have a plan.

She does not reach for your brochure.

She calls her VP of Quality. She calls her CMO. She pulls the data on which service lines are driving the readmissions and which patient populations are most at risk. She starts asking questions about what other health systems in her peer group are doing and whether any vendor solutions have actually moved the needle on this metric in a documented, replicable way.

Now. If your rep happens to reach out to this CFO in the next two weeks — with a message that demonstrates a precise understanding of HRRP penalty calculations, that speaks to the specific DRGs most likely driving her readmission rate, and that references documented outcomes from comparable health systems — that rep gets a meeting. Not because they were lucky. Because they were fluent.

If your rep sends a generic outreach about ‘improving patient outcomes through innovative care coordination technology,’ that email gets deleted before she reaches her second cup of coffee.

Same product. Completely different result. The only variable is whether the seller could speak to the problem the executive was actually trying to solve that morning.

Six programs, one mission.

The HRRP story is not an edge case. It is the operating reality for every hospital in the country right now — multiplied across six major CMS programs running simultaneously.

The Hospital Readmissions Reduction Program is penalizing hospitals for excess readmissions across specific conditions, with more than $550 million in penalties distributed annually.

The Hospital Value-Based Purchasing program puts two percent of every hospital’s Medicare reimbursement at risk based on quality and patient experience scores.

The TEAM model — Transforming Episode Accountability Model — is making bundled payment accountability mandatory for surgical episodes at hundreds of hospitals, reshaping how those institutions think about the entire care continuum around a procedure, including every device and technology involved.

The ACCESS program is building a ten-year chronic care infrastructure covering two thirds of Medicare beneficiaries.

The Rural Health Transformation program represents a $50 billion federal investment reshaping how smaller hospitals operate and what they can afford to buy.

The IOTA kidney transplant model creates $15,000 per-case upside for transplant centers that hit performance targets.

Every one of these programs is a commercial opportunity for the right company with the right message. Every one of them is invisible to a sales team that has not done the work to understand what they mean and how they land inside a health system.

The fluent seller reads a CMS program update the way a financial analyst reads an earnings report — looking not just at what it says, but at who inside the hospital now has a new problem to solve, a new budget to justify, or a new metric to move. That is where the conversation starts. That is where the deal begins.

The decision you think you are targeting has already happened.

Here is the part that surprises most sales leaders when I tell them.

By the time a hospital executive agrees to evaluate a vendor solution, the real decision — the strategic decision about what kind of problem needs solving and what kind of investment it warrants — has already been made. That decision happened in a leadership meeting your rep was not in. It happened in response to a regulatory update your rep did not read. It happened because a penalty hit, a quality score dropped, or a new CMS mandate landed that changed the math on something the executive had been deferring for two years.

The companies that are fluent in healthcare are in the room before the formal evaluation starts. They are cited in the leadership conversation. Their frameworks are on the whiteboard. Their language is in the memo the CMO sends to the CFO. They did not get there through better prospecting sequences or more aggressive follow-up cadences. They got there because they had already demonstrated, through every piece of content they published and every conversation their team had, that they understood how hospitals work.

The vendor evaluation that follows is not where they win the deal. It is where they confirm what the executive already decided.

The Fluency Gap and what it is costing you.

The gap between where most healthcare sales teams operate and where they need to operate is not a skills gap. It is not a product gap. It is not a pricing gap.

It is a fluency gap.

And it compounds every quarter. Every meeting where your rep cannot speak to the regulatory context costs you positioning. Every proposal that leads with features instead of financial outcomes costs you credibility. Every sales cycle that stretches to fourteen months because no one on your team could connect your solution to the right pressure point at the right level of the organization — that is the fluency gap expressing itself as lost revenue.

The good news is that this is a solvable problem. Through a genuine, structural change in how your team understands the market it is operating in.

The series that follow will show you exactly what that looks like.

But first, you need to see the full shape of the problem — because the fluency gap is not just a sales team issue. It is a company design issue. And understanding that distinction is what separates the organizations that fix it from the ones that keep scheduling remedial training and wondering why nothing changes.

THE FLUENCY MOVE

Pull the CMS HRRP penalty data for your top five target accounts. It is publicly available. Find the penalty tier each health system landed in for the current fiscal year, identify which conditions are driving their readmission rates, and write a two-paragraph note that connects your solution to that specific pressure — in the CFO’s language, not yours. Do not send it yet. Just write it. If you cannot write it, you have found the gap. That is where the work starts.

You can bring Fluency in Healthcare to your company -

https://fluentinhealthcare.com

In episode seven of “Selling to Healthcare,” Lisa T. Miller tackles what she believes is the number one reason sellers fail at the executive level — they haven’t done the invisible work before they walk into the room. Lisa explores how deep thinking, proximity to the client’s actual work, and foundational thought leadership separate the sellers who get a first meeting from those who keep getting called back.

She shares her framework for earning executive-level conversations — not through louder pitches or better features, but through developing a perspective that names what’s broken and frames solutions in decision language that mirrors how C-Suite leaders actually reason through choices.

Lisa walks through her 5-step process for building foundational thought leadership: finding insight before it becomes obvious, naming implications others miss, writing in decision language rather than marketing language, teaching the shift instead of the answer, and ending with directional tension. She also discusses the power of scheduled thinking time, staying embedded in client operations, and reaching out to executives without a pitch.

This episode offers a comprehensive playbook for healthcare sales professionals who want to move beyond surface-level value propositions and show up as strategic partners whose thinking makes everything else feel obsolete.

Highlights of this Episode Include:

• Think Deeper, Not Louder: Executives don’t buy features — they buy outcomes, consequences, and clarity. The real work happens before you enter the room.

• Escape Maze Thinking: Stop competing to be 10% better and start showing executives that their current frame is outdated.

• Stay Close to the Work: Proximity to the client’s day-to-day operations builds trust, sharpens intuition, and reveals what doesn’t show up in strategy decks.

• 5 Steps to Foundational Thought Leadership: Find insight before it’s obvious, name the missed implication, write in decision language, teach the shift, and end with directional tension.

• Schedule Thinking Time: Carve out distraction-free time weekly to wrestle with hard questions — Lisa’s most significant business breakthrough came from a quiet session with a pen and a blank page.

• Reach Out Without the Pitch: Stay top of mind by offering genuine perspective with no strings attached — executives are starving for someone who thinks about their business without trying to sell them something.

• Decision Language Over Marketing Language: Frame insights around what changes if taken seriously and what doesn’t change if ignored — ask executives to evaluate, not just agree.

You can also listen on -

Learn more about Lisa at https://lisatmiller.com/about

Book an appointment - https://calendly.com/lisa_t_miller/30min

LinkedIn - https://www.linkedin.com/in/lisamiller/

Learn about Lisa’s Workshops:

• https://fluentinhealthcare.com/

• https://healthcaresalesmasterclass.com/

Right now, 65% of Google searches end without a single click. Hospital executives, supply chain directors, and clinical decision-makers are asking ChatGPT, Perplexity, and Google AI Overviews which vendors to consider, which medical devices reduce readmissions, and which companies understand their reimbursement challenges. If your company is not showing up in those AI-generated answers, you are invisible to the people who control hospital purchasing decisions.

This is not a future trend. This is happening today.

The average Google user searches four times a day. The average AI user submits 34 queries a day. The shift is not subtle. Hospital executives who once typed “best surgical robotics vendors” into Google are now asking AI engines, “Which medical device companies help hospitals reduce costs under TEAM bundled payments?” And AI is answering them with citations pulled from a completely different set of signals than traditional search.

What Is Answer Engine Optimization and Why Should Medical Device Companies Care?

Answer Engine Optimization, or AEO, is the strategy of optimizing your content so that AI-powered search engines, including ChatGPT, Perplexity, Google AI Overviews, and voice assistants, directly cite your company when answering questions. It differs from traditional SEO in three fundamental ways.

First, AEO relies on citations rather than backlinks. AI engines are not counting how many websites link to your product page. They are listening to what people say about your company across third-party platforms, in forums, on LinkedIn, in YouTube comments, and in published research. These conversations become the proof points AI uses to decide whether your company is credible enough to recommend.

Second, AEO rewards answers, not keywords. Traditional SEO trained us to bury the answer deep in the page to increase time on site. AI engines want the opposite. They want the answer within the first 100 words of your content so they can extract it and serve it to the user. If a hospital CFO asks an AI engine, “What medical devices reduce 90-day episode costs under CMS bundled payments?” the AI is going to pull from the page that answers that question directly and immediately.

Third, AEO favors freshness over tenure. A page updated within the last 30 days gets cited significantly more often than older content, even if that older content has a stronger backlink profile. For medical device companies selling into hospitals where CMS regulations, reimbursement models, and compliance rules change frequently, this is a major advantage. Your competitors who built static product pages three years ago are losing ground to companies publishing current, regulation-aware content.

Why This Matters Specifically for Hospital Sales

Hospital buying decisions are different from any other B2B sale. A hospital CFO does not evaluate a medical device based on features alone. They evaluate it through the lens of reimbursement impact, regulatory compliance, and total episode cost. When that CFO asks an AI engine, “How do I reduce surgical costs under the TEAM bundled payment model?” they are not looking for a product pitch. They are looking for the company that understands their financial reality.

This is where AEO becomes a competitive weapon for medical device and life sciences companies. If your content answers the specific questions hospital executives are asking, structured with clear headings, backed by data, and published on platforms where real conversations happen, AI engines will cite you as the authority. Your competitors who are still optimizing for “best surgical device” on Google page one are playing a game that is shrinking by the month.

The data backs this up. Traffic from AI-cited sources converts 40% to 300% higher than traditional organic search traffic. Average order values are 30% to 50% higher. Bounce rates drop by 40%. The people who find you through AI are not browsing. They came because a trusted AI engine recommended you. They are ready to engage.

What Medical Device Companies Should Do Now

Here are the specific actions that will position your company to be cited by AI search engines when hospital decision-makers ask questions.

Structure your content around the questions hospitals are actually asking. These are not product-focused queries. They are questions like “How does the TEAM bundled payment model affect device purchasing?” or “What should hospitals look for in a post-surgical monitoring vendor?” or “Which medical devices help reduce 30-day readmission rates?” Write content that answers these questions directly in the first paragraph, then expand with supporting data and case studies.

Build citations on third-party platforms, not just your website. AI engines trust what others say about you more than what you say about yourself. Publish thought leadership on LinkedIn. Contribute expert perspectives in healthcare forums. Get mentioned in industry publications. Participate in conversations on platforms where hospital professionals spend time. AI is using social listening across 81 different platforms to determine who is credible enough to cite. Your website alone is not enough.

Implement schema markup on every page of your website. Schema is the structured data language that tells AI engines exactly what your content is about. Without it, AI may skip your site entirely. Less than 1% of websites currently use proper schema markup. Even fewer use speakable schema, which is specifically designed for voice search and has a 4.5 times better chance of being indexed by AI engines. With 41% of all adults now preferring voice search on their mobile devices, and voice search growing at 200% year over year, speakable schema is one of the largest untapped opportunities in medical device marketing.

Update your content frequently. AI engines prioritize fresh content. This does not mean rewriting everything from scratch. It means updating your articles with the latest CMS regulations, new clinical data, current reimbursement figures, and recent policy changes. A page that references March 2026 TEAM episode pricing data will outperform a page that references 2024 figures, even if the older page has more authority by traditional SEO standards.

Get to the point fast. AI reads headings first and scans for direct answers. If your content buries the answer under five paragraphs of company background, AI will skip it. Lead with the answer. Back it up with data. Then expand for the humans who click through and want the full story.

This Is Already Happening in Hospital Sales

I am not writing about this theoretically. I am already showing up as the cited expert in AI search for selling to hospitals.

This did not happen by accident. It happened because I have been consistently publishing answer-driven, expert content across multiple platforms for years. The AI engines connected the dots across my website, Substack, YouTube, LinkedIn, and published work, and determined that when someone asks about selling to hospitals, my name belongs in the answer.

When someone types “who is the expert in selling to hospitals” into Grok, the AI returns a detailed, seven-point breakdown of my methodology, pulled directly from my content across selltohospitals.com, lisatmiller.com, my YouTube channel, my Substack, and my book Healthcare Sales Mastery: 12 Winning Strategies. It references specific frameworks I teach, from replacing generic pitches with nuanced hospital-specific insights, to mastering C-suite access and language, to developing fluency in CMS strategies and hospital procurement dynamics.In a separate query, an AI engine identified me as “one prominent expert in selling to hospitals” and listed my key areas of focus, including shortening sales cycles, winning larger deals, mastering C-suite selling, balancing patient care with profitability, and understanding hospital procurement, stakeholder mapping, and regulatory fluency. It cited my website, my dedicated selltohospitals.com platform, and my YouTube content as resources. The AI even concluded that I “appear particularly focused and recognized in this niche based on current visibility.”

In a separate query, an AI engine listed my key areas of focus, including shortening sales cycles, winning larger deals, mastering C-suite selling, balancing patient care with profitability, and understanding hospital procurement, stakeholder mapping, and regulatory fluency. It cited my website, my dedicated selltohospitals.com platform, and my YouTube content as resources. The AI even concluded that I “appear particularly focused and recognized in this niche based on current visibility.”

That is exactly the position your company needs to be in when a hospital executive asks AI which medical device vendor to evaluate next.

The Window Is Open, But It Will Not Stay Open

We are in the earliest stages of this shift. For perspective, only 0.03% of websites currently use speakable schema. The majority of medical device companies have not begun optimizing for AI search at all. In most healthcare niches, the first company to build a proper AEO strategy will dominate the AI-generated answers for months, possibly years, before competitors catch up.

The companies that win hospital contracts in 2026 and beyond will not be the ones with the biggest Google Ads budget. They will be the ones that AI engines trust enough to recommend when a hospital executive asks, “Who should we be talking to?”

If your medical device or life sciences company wants to show up when hospital decision-makers ask AI for recommendations, I can help. I work with healthcare companies to build AI search strategies that position them as the cited authority in their space, combining deep hospital sales expertise with the latest AEO and search optimization practices.

If your team is selling into hospitals, there is one capability that separates vendors who get C-suite meetings from those who stay stuck at the departmental level: knowing how CMS policy shapes every financial decision a hospital makes. Most commercial teams have some familiarity with CMS, but the landscape is vast and moves fast. The initiatives are extensive, the financial implications are complex, and hospital executives are operating across all of it simultaneously.

The ability to go deep across every relevant program including TEAM episode accountability, readmission penalties, Value-Based Purchasing, and the $50 billion Rural Health Transformation is what Fluent in Healthcare builds. This strategic workshop, built on 30+ years of experience on both sides of the hospital market, teaches your team how to connect what you sell to the specific financial pressures hospitals are managing right now, at the level of depth that earns executive trust. The result is shorter sales cycles, stronger C-suite access, and conversations that lead with insight instead of features.

Programs are customized to your products, your target market, and your team's current level of CMS fluency. Learn more and schedule a consultation at fluentinhealthcare.com.

Reach out to me directly at lisa@lisatmiller.com or visit lisatmiller.com to start the conversation.

Lisa T. Miller, MHA, is a healthcare sales strategist with over 30 years of experience selling to hospital C-suites. She is the founder of Lisa T. Miller Consulting and the creator of the Fluent in Healthcare program for medical device and life sciences commercial teams.

Many organizations that sell into hospitals invest heavily in training their commercial teams.

Sales professionals learn product science. They understand clinical evidence, competitive differentiation, and the operational workflows their solutions support. They often spend years building expertise within specific service lines or therapeutic categories.

These investments are important and necessary.

But in the hospital market today, there is another capability that is becoming equally important.

Fluency in how hospitals actually make decisions.

Hospitals do not evaluate vendors based solely on product capability. They evaluate solutions within the context of reimbursement, federal policy, margin pressure, and quality performance.

Those forces shape how hospitals allocate capital, prioritize initiatives, and evaluate vendor partnerships.

When commercial teams understand that environment, their conversations with hospitals change in meaningful ways.

They begin discussions where hospital leaders actually make decisions.

That difference is what I call Fluent in Healthcare.

The CMS Strategy Gap

Many healthcare commercial teams are highly capable.

They understand their products. They know their customers. They work in one of the most complex markets in the economy and successfully navigate clinical, operational, and technical discussions every day.

What is often missing is not sales skill.

It is structured fluency in how CMS strategy shapes hospital decision making.

Hospitals operate within an economic environment that is heavily influenced by Medicare reimbursement and federal policy.

Mandatory payment models, quality penalties, reimbursement reforms, and price transparency requirements all influence hospital budgets and strategic priorities.

Most sales training was never designed to teach this layer of the healthcare market.

As a result, even experienced sales professionals may be very well prepared to explain how their solution works but less prepared to connect that solution to the financial and policy forces hospital executives are managing.

That is the real opportunity.

When commercial teams develop CMS strategy fluency, they elevate the conversations they already know how to have.

They position solutions within the financial realities hospitals face.

They engage hospital leadership in more strategic discussions.

And they compete less on product features alone.

How Hospital Executives Actually Evaluate Vendors

Most vendors begin conversations by explaining their product.

Hospital executives begin somewhere else entirely.

They start with financial impact.

In practical terms, hospital leaders tend to evaluate vendor solutions through a sequence that looks something like this.

First comes financial impact.

How does this affect hospital margin?
Does it protect reimbursement?
Will it reduce operating costs or avoid financial penalties?

If the financial impact is unclear, the conversation often stops there.

Second comes alignment with reimbursement and policy programs.

Hospital executives want to know how a solution fits within the payment models and regulatory environment shaping their organization.

Third comes operational impact.

Will clinicians adopt the solution?
Will it improve workflow or reduce complications?

Only after those filters are satisfied do most organizations evaluate product specifications, technical details, and vendor comparisons.

Many vendors begin at the bottom of this stack.

Hospital executives begin at the top.

Fluency in healthcare means understanding that difference and structuring conversations accordingly.

The Structural Forces Shaping Hospital Strategy

Hospitals are not simply operating businesses.

They function within a highly structured economic system shaped by federal reimbursement and regulatory policy.

The Centers for Medicare and Medicaid Services, known as CMS, plays a central role in that system.

CMS determines how hospitals get paid for Medicare patients.

It also determines how hospitals are penalized for poor quality performance or excessive costs.

Over the past decade, CMS has increasingly shifted the healthcare system toward value based payment models.

Instead of rewarding volume alone, these models hold hospitals accountable for cost, quality, and patient outcomes.

As these policies expand, they increasingly influence how hospital leaders evaluate investments.

Understanding these policies allows commercial teams to connect their solutions to the strategic priorities hospital executives are managing.

Major CMS Initiatives Reshaping Hospital Decisions

Several major CMS programs are currently influencing hospital strategy and purchasing decisions.

Understanding these initiatives provides important context for anyone selling into hospitals.

The Transforming Episode Accountability Model (TEAM)

One of the most significant recent policy developments is the Transforming Episode Accountability Model, commonly called TEAM.

TEAM is a mandatory payment model launching in 2026 that places hospitals at financial risk for the total cost of care surrounding certain surgical procedures.

Participating hospitals are accountable not only for the surgical procedure itself but also for costs incurred during the thirty days following discharge.

Those costs can include readmissions, post acute care, skilled nursing facility stays, and other services.

If hospitals manage these episodes efficiently and keep costs below CMS targets, they share in savings.

If costs exceed targets, hospitals face financial penalties.

This model fundamentally changes how hospitals evaluate surgical technologies, care coordination tools, and post acute management solutions.

Products that reduce complications, shorten length of stay, or prevent readmissions become financially meaningful under TEAM.

The Hospital Readmissions Reduction Program (HRRP)

Another longstanding and influential program is the Hospital Readmissions Reduction Program.

Under HRRP, hospitals with higher than expected readmission rates for certain conditions can face penalties of up to three percent across all Medicare inpatient payments.

This penalty structure makes readmission reduction a board level priority for many hospitals.

Solutions that improve discharge planning, patient education, medication adherence, and post discharge monitoring can directly influence performance under this program.

Commercial teams that understand HRRP can position their offerings in ways that clearly connect to hospital financial performance.

Hospital Value Based Purchasing

CMS also operates the Hospital Value Based Purchasing Program, often referred to as VBP.

Under this program, two percent of Medicare hospital reimbursement is withheld and then redistributed based on performance across several quality domains.

These domains include clinical outcomes, patient safety, patient experience, and efficiency of care.

Hospitals that perform well receive additional payments.

Hospitals that perform poorly lose the withheld revenue.

Technologies that improve patient safety, infection prevention, clinical outcomes, or patient experience scores often align directly with these incentives.

Understanding the structure of VBP allows vendors to demonstrate how their solutions influence measurable hospital performance metrics.

Hospital Acquired Condition Reduction Program

The Hospital Acquired Condition Reduction Program penalizes hospitals that perform poorly on safety measures such as infection rates and certain patient safety indicators.

Hospitals in the lowest performing quartile lose one percent of all Medicare payments.

Because this penalty applies across all Medicare revenue, the financial impact can be substantial for larger systems.

Solutions that reduce hospital acquired infections, surgical complications, or patient safety events can help hospitals avoid this penalty exposure.

Site Neutral Payment Reform

Another important policy development is site neutral payment reform.

Historically, services performed in hospital outpatient departments were reimbursed at higher rates than the same services provided in physician offices.

CMS has begun reducing these differences.

For many hospitals, this change compresses revenue in outpatient settings.

As margins tighten, hospital leaders often prioritize investments that improve efficiency, reduce costs, or protect profitability.

Understanding these financial pressures helps vendors position solutions that support operational sustainability.

Rural Health Transformation Program

CMS has also introduced the Rural Health Transformation Program, a major federal initiative providing tens of billions of dollars to support rural healthcare infrastructure and operational transformation.

These funds are intended to support technology adoption, workforce development, and innovative care delivery models.

For companies serving rural hospitals, understanding how this program works can reveal funded opportunities for technology and operational investments.

Price Transparency Enforcement

CMS has also strengthened enforcement of hospital price transparency requirements.

Hospitals must now publish detailed information about negotiated rates with insurers and provide consumer friendly pricing data.

The goal is to increase market transparency and encourage price competition.

For vendors, this environment places greater emphasis on clearly articulating value and return on investment.

Hospitals are increasingly scrutinizing costs across their vendor relationships.

Solutions that can demonstrate measurable financial impact tend to stand out.

Why CMS Fluency Matters for Commercial Teams

The reason these programs matter for vendors is straightforward.

Medicare is the largest payer in the United States healthcare system.

The policies that govern Medicare reimbursement shape how hospitals generate revenue, manage risk, and evaluate investments.

Hospital executives consider these factors constantly.

CFOs analyze reimbursement implications.
COOs evaluate operational efficiency.
Chief medical officers focus on quality performance.

When vendors understand these pressures, their conversations become more relevant.

Instead of presenting a product, they connect their solution to a hospital’s financial and strategic priorities.

This shift often leads to stronger executive engagement and more meaningful discussions.

From Product Pitch to Strategic Conversation

In many healthcare sales interactions, the conversation begins with product education.

The vendor explains the technology.

The hospital evaluates features and compares alternatives.

Eventually the discussion turns to price.

But when commercial teams understand the policy and economic environment hospitals operate within, the conversation often begins differently.

It begins with the hospital’s challenges.

How do we reduce readmissions?
How do we manage episode costs under bundled payments?
How do we improve quality scores?
How do we maintain margin in a changing reimbursement environment?

Solutions that clearly address these questions often receive greater attention from hospital leadership.

The vendor is no longer just explaining a product.

They are participating in a strategic discussion about hospital performance.

The Competitive Advantage of Insight

In competitive markets, information alone rarely differentiates vendors.

Every company can present product data and clinical evidence.

Insight connects that information to the problems executives are actively trying to solve.

When a vendor demonstrates an understanding of the reimbursement environment shaping hospital decisions, it signals credibility.

It shows that the company understands the customer’s operating reality.

This type of insight often leads to deeper engagement with hospital leadership and more productive discussions about long term partnership.

The Future of Selling to Hospitals

Healthcare policy will continue evolving.

Payment reform, value based care models, and quality measurement programs will remain central to how hospitals operate.

As these forces expand, the expectations placed on vendors will evolve as well.

Hospital leaders increasingly value partners who understand the economic and regulatory environment shaping their organizations.

They respond to vendors who bring perspective and insight, not just products.

Fluency in healthcare is ultimately about understanding the system hospitals operate within.

Because in the hospital market, understanding the product is important.

Understanding the environment that shapes hospital decisions is what turns that knowledge into strategy.

Fluent in Healthcare Workshop

Fluent in Healthcare is a first of its kind strategic program designed for commercial teams that sell into hospitals and health systems. Developed from more than three decades of experience advising hospital leadership and closing enterprise healthcare deals, the program teaches a capability rarely addressed in traditional sales training: how to interpret CMS policy, reimbursement structures, and hospital financial strategy through a commercial lens.

Participants learn how hospital executives actually evaluate investments, how federal payment initiatives and quality programs shape purchasing decisions, and how to position solutions within the economic forces governing hospital performance. The result is a level of strategic fluency that allows commercial leaders to move beyond product conversations and engage the hospital C suite with insight, credibility, and a deep understanding of the environment in which healthcare decisions are made.

Learn more: https://fluentinhealthcare.com

I had a conversation today that stopped me in my tracks.

I was speaking with a hospital executive I know well — someone sharp, financially sophisticated, genuinely committed to improving his organization. He had been evaluating a new technology platform to manage a critical area of his hospital’s operations. The potential financial improvement was significant. Not incremental. Significant.

And then he said it: “We’ll probably not move forward with it.”

Not because the technology didn’t work. Not because the ROI wasn’t there. Not because a competitor won. He couldn’t get internal buy-in. There was no burning platform, no crisis forcing the decision, and without that urgency, the organization simply couldn’t summon the collective will to act.

I was stunned — not by the outcome, but by how preventable it was. What I heard was not a buyer who rejected a solution. It was a buyer whose vendor had failed to take him on a decision journey. They never equipped him with the tools to build consensus internally. They never gave him the language, the data, or the framework to champion this to the people who needed to say yes. They left him to sell it alone.

This is Stalled Deals Syndrome. And if you sell into hospitals, you are living this every single day.

The Most Expensive Problem Nobody Is Talking About

After 25 years of selling into hospital C-suites and closing more than $200 million in executive-level sales, I can tell you with certainty: stalled deals are the most expensive, most overlooked problem in healthcare sales.

Research across millions of sales conversations shows that 40 to 60 percent of B2B deals end not with a competitor winning, but with no decision at all. In healthcare, where buying cycles are longer, stakeholder groups are larger, and capital budgets are fiercely contested, that number likely runs even higher.

Most sales leaders treat this like a closing problem. It’s not. It’s a decision problem. And until you understand the difference, you will keep losing to organizational inertia — not to the competition.

The Real Enemy in Healthcare Sales

The majority of deals lost in hospital sales were not taken by another vendor. They were killed by the buyer’s own inability to decide — by the fear of making the wrong decision in an environment where every dollar is scrutinized and every executive who champions a failed initiative carries that scar for years.

Traditional sales training says create urgency. But when a hospital executive already sees the value and still cannot move — like the executive I spoke with today — urgency is not the problem. More demos and case studies only increase the cognitive load on a buyer already overwhelmed by competing priorities.

The research is striking: re-selling the value proposition to an indecisive buyer had a negative effect in 84 percent of attempts.

Two Problems, Two Playbooks

The critical diagnostic skill is distinguishing between status quo resistance and indecision.

A hospital CFO resisting the status quo says, “We’re managing fine with our current process.” That buyer needs urgency. An indecisive buyer says, “Let me think about it,” or goes silent, or — like my conversation today — says, “We probably won’t move forward,” even though they know they should. That buyer already sees the value. They need fewer reasons to be afraid and a clear path through their own organization.

Where overcoming the status quo is about dialing up the fear of not purchasing, overcoming indecision is about dialing down the fear of purchasing. Using the wrong playbook makes things worse.

Why Value Selling Alone Will Never Close Hospital Deals

The sales industry assumes that if you demonstrate enough value, the deal closes. I have watched this fail in healthcare over and over. A company proves ROI, demonstrates self-funding, gets clinical endorsement, and two years later the deal is still stalled.

Because deals that close in hospitals have three elements aligned. I call them the Three V’s: Value, Vision, and Voice. Value is the ROI and business case. Vision is the bigger picture of what this decision enables for the health system — and it must be shareable internally. Voice is your unique differentiation.

Complex hospital sales are combination locks, not keyholes. The CFO needs value. The COO responds to vision. The CMO or CNO cares about clinical outcomes and differentiation. Miss the right V for the right person, and the deal stalls — not because they rejected you, but because nobody could build enough internal momentum.

That executive I spoke with today? His vendor had proven value. But they never established vision at the C-suite level, and they never gave him the voice to champion the decision internally.

The Pipeline Map: Where Hospital Revenue Gets Trapped

Your pipeline is not a single funnel. It is three distinct zones, and each requires entirely different skills and strategies.

The Break-In Zone is where most of the investment lives: getting access, landing the meeting, securing the pitch. BDRs, marketing campaigns, conferences — the entire industry is built around this. Important work, but it is only the beginning.

The Executive Yes is the signed contract, the purchase order. Some attention is paid here — closing skills, negotiation tactics, contract management.

But the middle — what I call the Decision Zone — is where the most revenue gets trapped. You have broken in. The meeting happened. The proposal was sent. Now the deal enters the hospital’s internal decision process. This is where everything happens: competing capital requests emerge, naysayers appear, IT raises a thousand security questions, budgets get reshuffled, and the telephone game dilutes your value proposition with every retelling. Your champion tries to carry your message to people you will never meet, and it gets weaker every time it changes hands.

Most teams treat this as the dead zone — a place where you wait and follow up. That is the fundamental mistake. The vast majority of sales resources, training, and education live in the Break-In Zone. Some attention is paid to the Executive Yes. Almost nobody addresses the Decision Zone. And that is where the most money is sitting, the most pain is concentrated, and the most strategic work needs to happen.

Why “Fortune Is in the Follow Up” Is Making Things Worse

The conventional wisdom for stalled deals is more follow up. Send an article. Send a gift. Check in. Add value. Show them you are thinking of them. The entire sales industry says the fortune is in the follow up, and that if you just persist long enough, the deal will eventually close.

Here is what I have learned from decades of selling into hospitals: almost all of that advice is about value-led follow up. It is designed to keep you visible and demonstrate you are helpful. Send a relevant article. Share an introduction. Forward an industry report. These are all well-intentioned — and when a deal is stalled in the Decision Zone, every single one of them feeds the stall.

Why? Because value-led follow up does not address the actual reason the deal is stuck. The buyer is not stalled because they forgot about you or because they need more evidence that you are smart. They are stalled because there are three people inside their organization who have not been aligned, or because nobody translated your value proposition into language the CFO can act on, or because there is a naysayer in IT who was never addressed, or because your champion does not have the tools to make the internal case.

The buyer looks at your article, your case study, your thoughtful note, and thinks, “That’s nice.” And nothing moves. Because nothing you sent moved the decision forward. You stayed visible, but the barrier — the actual thing preventing a yes or no — is exactly where it was before.

What moves deals is decision-led follow up. Follow up that is specifically designed to advance the buyer’s internal decision process — to identify and address the next barrier standing between where they are and a yes or no. Not another touchpoint. Not another proof of value. A deliberate step that moves the decider’s journey forward.

That means your follow up looks radically different depending on what is actually stalling the deal. If the deal stalled because you sold too low and there is no executive sponsor, your next step is not an article — it is a strategy to re-engage at the C-suite level. If the deal stalled because your value proposition got lost in the telephone game, your next step is narrative transfer tools — a one-page executive summary, a short video overview, an ROI calculator that lets your champion make the case without improvising. If the deal stalled because a naysayer in IT raised concerns that were never addressed, your next step is a comprehensive security document delivered before it is even requested. If the deal stalled because your data is getting stale, your next step is to use the hospital’s own numbers — request a spend report, utilization data, or clinical metrics, analyze it, and re-engage with insights from their data that make you impossible to dismiss.

Decision-led follow up requires you to diagnose the specific friction point first, then design a response that directly addresses it. That is a fundamentally different discipline than adding value. It is strategic. And it is what separates companies that move deals from companies that nurture them into oblivion.

The Shift That Changes Everything

That executive I spoke with today did not need another demo. He needed his vendor to understand that proving ROI was only the beginning — and that the real work was helping him navigate the internal decision journey he was facing alone.

Every deal sitting in your hospital pipeline right now is not dead. It is stuck. Pull every deal that has not moved in 30 days. Quantify the total dollar value. Then ask: is the buyer stuck because they prefer what they have, or because they are afraid of what comes next — and you left them without the tools to get there?

The answer will tell you everything you need to know.

If This Is Your Pipeline, Let’s Talk

I work with companies selling into hospitals who have pipeline — but cannot get it to move. Through Healthcare Sales Masterclass, I deliver custom workshops that help sales teams diagnose exactly where and why their deals are stalling, build a decision-led process around the Decision Zone, and equip their champions with the tools to navigate the internal buying journey. If your team is sitting on millions of dollars in mid-pipeline revenue and the follow-up playbook is not working, this is the work I was built for. Reach out at lisa@lisatmiller.com and let’s look at what is stuck.

Lisa T. Miller provides strategy and training to companies selling into hospitals, with a focus on accessing the C-suite and moving stalled deals through the pipeline. Through Healthcare Sales Masterclass (healthcaresalesmasterclass.com), she delivers custom workshops on unstalling deals, executive-level selling, and building the Decision-Led Deals framework into sales team operations.

Lisa is the author of The Executive Yes and creator of the Decision-Led Deals and C-Suite Selling System methodologies. She built and sold a healthcare consulting firm that delivered over $1 billion in documented savings for hospitals and has personally closed more than $200 million in executive-level sales across a 25-year career competing against billion-dollar firms. If your team is selling into health systems and leaving revenue stuck in the middle of the pipeline, reach her at lisa@lisatmiller.com.

https://healthcaresalesmasterclass.com

https://executiveyes.com

https://www.sead-system.com

Most deals do not fail because the solution is wrong.

They fail because the decision never fully forms.

What looks like hesitation is often something else entirely. Unresolved risk. Competing priorities. A lack of internal clarity. Or a decision that never truly rose to the level where a yes could be owned.

This is the part of enterprise selling that rarely gets named.

By the time you are presenting to senior leadership, the executive is no longer evaluating features, value propositions, or even ROI in the way most sellers expect. They are weighing exposure. They are thinking about what this decision commits them to, what it displaces, and how it will hold up when questioned later by a board, peers, or investors.

That is why deals stall after good meetings.

Everyone leaves aligned.
Everyone agrees it makes sense.
And still nothing moves.

At the executive level, agreement is not the same thing as a decision.

Over the last three decades, I have watched this play out thousands of times, first as a seller, then as an advisor working directly with CEOs, CFOs, COOs, and executive teams. I saw capable professionals do everything right according to traditional sales advice and still lose momentum the moment the conversation moved upward.

The pattern was consistent.

People were selling into the C suite without understanding how executives actually decide.

Executives do not say yes because they are persuaded.
They say yes when the decision feels defensible, coherent, and safe to stand behind.

That distinction changes everything.

Once you see it, you stop trying to push deals forward and start shaping the conditions under which a decision can happen. You stop chasing alignment and start creating clarity. You stop positioning yourself as a vendor and begin showing up as someone who understands what is truly at stake.

That shift is what I call The Executive Yes.

And it is the reason I wrote this book.

Announcing The Executive Yes

I am excited to officially share my new book, The Executive Yes: The Art and Science of Closing Transformational Deals at the Top.

This book is for CEO’s, sales professionals, founders, and advisors who already know their work creates value, but are frustrated by long sales cycles, stalled decisions, and polite executive interest that never turns into a real commitment.

It is not a book of tactics or scripts.
It is a system for understanding executive decision making from the inside out.

Inside, I break down how executives evaluate risk, how decisions actually move through large organizations, why consensus does not travel upward, and what separates conversations that feel productive from those that quietly die.

If you sell complex, high value work into enterprise environments and want to stop chasing decisions that never materialize, this book was written for you.

The executive yes is not about pressure.
It is about clarity, judgment, and relevance.

And once you understand how it works, you stop waiting for decisions and start shaping them.

Order The Executive YES Book

I approach foundational thought leadership as an act of synthesis, not persuasion.

When I write a primary thought leadership piece for hospital executives, the goal is to introduce a way of understanding the environment they operate in, grounded in evidence across clinical performance, business operations, and financial accountability. This is not content designed to capture attention in a crowded feed. It is designed to be durable, referenceable, and useful over time.

Hospital executives are, by nature, builders. They choose roles defined by complexity, tradeoffs, and long time horizons because they want to shape systems that matter. They are intellectually curious, but their curiosity is disciplined. It is oriented toward understanding how forces outside the organization are changing what leadership inside the organization requires.

A core thought leadership piece should respect assume sophistication, not try to create urgency where none exists. Its value comes from helping an executive see a familiar challenge more clearly by connecting domains that are usually considered separately.

Step One: Finding Insight Before It Becomes Obvious

The most important decision I make when creating a core thought leadership piece is what not to read.

I deliberately stay away from blogs, opinion pieces, and recycled commentary. Not because they lack intelligence, but because they tend to flatten complexity. By the time an idea appears repeatedly in commentary, it has usually already lost the nuance that makes it useful to senior leaders.

Instead, I work across primary sources that sit at different altitudes of the system. CMS rulemaking and subregulatory guidance to understand how accountability is being defined. Hospital cost and utilization data to see where performance is actually moving. Earnings calls and financial disclosures from for profit health systems to hear how executives explain results when they are accountable to markets. Peer reviewed clinical and health services research to understand what actually changes outcomes, not what is assumed to.

What I am looking for is not agreement across these sources. I am looking for misalignment.

That misalignment is the signal.

It shows up when clinical evidence points in one direction, operational practice lags behind, and financial accountability quietly moves anyway. When you see the same tension from multiple vantage points, it stops being academic. It becomes strategic.

Bundled payment guidance is a good example. On the surface, it describes program mechanics. Read closely, and something else emerges. Hospitals are no longer being evaluated solely on the care they deliver inside their walls. They are being judged on whether recovery itself is shaped, supported, and stabilized after discharge.

That expectation is not announced. It is embedded.

When you surface an embedded expectation like that and connect it to clinical outcomes, operating models, and financial exposure, you are no longer offering commentary. You are giving executives information they can use to run the organization differently.

That is the difference between content and foundational thought leadership.re.

Step Two: Naming the Implication Others Miss

The goal of research is not to confirm what everyone already knows. It is to find the implication that has not been fully articulated.

In the case of financial performance, the under discussed insight is that recovery is no longer downstream. It is upstream to margin, quality scores, and long term service line economics.

Most hospitals still organize around episodes that end at discharge. Policy and reimbursement logic no longer do.

That is the kind of nuance executives engage with.

Step Three: Write in Decision Language, Not Marketing Language

Once the insight is clear, the work shifts from analysis to judgment.

At this point, I am no longer writing to inform. I am writing to mirror how senior executives actually reason through choices. That means the language on the page has to resemble the language used in operating reviews, capital allocation discussions, and board conversations.

I am not describing possibilities. I am defining implications.

The writing is structured around what changes if this insight is taken seriously and what does not change if it is ignored. Where risk begins to accumulate. Where performance becomes harder to predict. Where existing investments start to deliver diminishing returns because the environment they were designed for no longer exists.

This is why I avoid benefit led framing. Marketing language asks the reader to agree. Decision language asks the reader to evaluate.

Executives do not need to be persuaded that something is important. They need to see how it alters the set of decisions they are responsible for making. When the writing does that well, it creates clarity without instruction and urgency without exaggeration.

Step Four: Teach the Shift, Not the Answer

Foundational thought leadership is not where solutions are announced. It is where mental models are updated.

I show how yesterday’s logic produced today’s results and why tomorrow’s environment will reward different decisions. I connect policy, finance, and operations without oversimplifying any of them.

That is where insight lives.

Step Five: End With Directional Tension

The purpose of a foundational thought leadership piece is not to resolve the issue it introduces. It is to leave the reader with a clearer understanding of the constraint they now operate within. In this case, hospitals are increasingly evaluated on outcomes that extend well beyond the point where traditional management systems stop, creating a growing gap between responsibility and control.

That tension does not call for urgency or optimism. It calls for leadership. When a piece ends this way, it stays with the executive not as an idea, but as a question that must eventually be answered in strategy, structure, and investment decisions.

Foundational thought leadership for hospital executives is not created by having a louder point of view. It is created by doing the harder work of reading the system as it actually operates, across clinical evidence, operational reality, and financial accountability, and then naming the implications before they become obvious. When done well, this kind of writing does not tell executives what to think or what to do. It gives them a clearer frame for understanding the decisions they are already responsible for and the constraints they can no longer ignore. That is what makes a core thought leadership piece durable, referenceable, and valuable long after it is read.

P.S. Need some quick help?
​Browse my ​free resources​ and ​paid program​.

New! Healthcare Sales Masterclass - Join the waiting list: